<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001776.pub2" GROUP_ID="FERTILREG" ID="474899090214435764" MERGED_FROM="" MODIFIED="2010-01-12 15:58:30 +0100" MODIFIED_BY="Anja Helmerhorst" NOTES="&lt;table width=&quot;200&quot; cols=&quot;3&quot; rows=&quot;3&quot;&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;&lt;p&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Short title (no longer in use): IUSs vs. other contraceptive methods&lt;/p&gt;&lt;p&gt;&lt;br&gt;Old title: Hormonally impregnated intrauterine systems (IUSs) versus other forms of reversible contraceptives as effective methods of preventing pregnancy (Oxford versie)&lt;/p&gt;" NOTES_MODIFIED="2010-01-12 15:50:39 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0005" REVMAN_SUB_VERSION="5.0.23" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-01-12 15:50:39 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-25 14:24:19 +0100" MODIFIED_BY="[Empty name]">Progestogen-releasing intrauterine systems versus other forms of reversible contraceptives for contraception</TITLE>
<CONTACT>
<PERSON ID="16513573720558879117090810095709" MODIFIED="2010-01-12 14:55:11 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Annik</FIRST_NAME>
<MIDDLE_INITIALS>M.</MIDDLE_INITIALS>
<LAST_NAME>Sorhaindo</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>annik.sorhaindo@lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Public &amp; Environmental Health Research Unit</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>Keppel Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)20 79272660</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 (0)207 5804524</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-01-12 14:57:23 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="8892" MODIFIED="2010-01-12 14:54:44 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Ms</PREFIX>
<FIRST_NAME>Rebecca</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>French</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Lecturer in Sexual Health</POSITION>
<EMAIL_1>Rebecca.French@lshtm.ac.uk</EMAIL_1>
<EMAIL_2>hchandler@gum.ucl.ac.uk</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Public and Environmental Health Research Unit</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>Keppel Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)20 7927 2047</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="16513573720558879117090810095709" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Annik</FIRST_NAME>
<MIDDLE_INITIALS>M.</MIDDLE_INITIALS>
<LAST_NAME>Sorhaindo</LAST_NAME>
<SUFFIX/>
<POSITION>Research Fellow</POSITION>
<EMAIL_1>annik.sorhaindo@lshtm.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Public &amp; Environmental Health Research Unit</DEPARTMENT>
<ORGANISATION>London School of Hygiene &amp; Tropical Medicine</ORGANISATION>
<ADDRESS_1>Keppel Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E 7HT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 (0)20 79272660</PHONE_1>
<PHONE_2/>
<FAX_1>+ 44 (0)207 5804524</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13665" MODIFIED="2010-01-12 14:55:33 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Huib</FIRST_NAME>
<MIDDLE_INITIALS>AAM</MIDDLE_INITIALS>
<LAST_NAME>Van Vliet</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>haam.vliet@worldonline.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>0031-6-14362657</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Gynaecology, Division of Reproductive Medicine</DEPARTMENT>
<ORGANISATION>Leiden University Medical Center</ORGANISATION>
<ADDRESS_1>Albinusdreef 2</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leiden</CITY>
<ZIP>NL 2300 RC</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>0031-6-14362657</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13646" MODIFIED="2010-01-12 14:56:00 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>Diana</FIRST_NAME>
<MIDDLE_INITIALS>D.</MIDDLE_INITIALS>
<LAST_NAME>Mansour</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Family Planning</DEPARTMENT>
<ORGANISATION>Community Gynaecology and Reproductive Health Care</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Newcastle upon Tyne</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13655" MODIFIED="2010-01-12 14:56:30 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Dr.</PREFIX>
<FIRST_NAME>A.</FIRST_NAME>
<MIDDLE_INITIALS>A.</MIDDLE_INITIALS>
<LAST_NAME>Robinson</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Department of Infection &amp; Population Sciences</DEPARTMENT>
<ORGANISATION>Centre for Sexual Health &amp; HIV Research</ORGANISATION>
<ADDRESS_1>University College London, Gower Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E6BT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7809" MODIFIED="2010-01-12 14:56:33 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Stuart</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Logan</LAST_NAME>
<SUFFIX/>
<POSITION>Director of Health and Social Care Research</POSITION>
<EMAIL_1>stuart.logan@pms.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Institute of Health and Social Care Research</DEPARTMENT>
<ORGANISATION>Peninsula Medical School, Universities of Exeter &amp; Plymouth</ORGANISATION>
<ADDRESS_1>St Luke's Campus</ADDRESS_1>
<ADDRESS_2>Heavitree Road</ADDRESS_2>
<CITY>Exeter</CITY>
<ZIP>EX1 2LU</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 1392 262991</PHONE_1>
<PHONE_2/>
<FAX_1>+44 1392 262964</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="5555" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Frans</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Helmerhorst</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinating Editor, Cochrane Fertility Regulation Group</POSITION>
<EMAIL_1>f.m.helmerhorst@lumc.nl</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gynaecology, Division of Reproductive Medicine and Dept. of Clinical Epidemiology</DEPARTMENT>
<ORGANISATION>Leiden University Medical Center</ORGANISATION>
<ADDRESS_1>PO Box 9600</ADDRESS_1>
<ADDRESS_2>Albinusdreef 2</ADDRESS_2>
<CITY>Leiden</CITY>
<ZIP>NL 2300 RC</ZIP>
<REGION/>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<PHONE_1>+31 71 5262871</PHONE_1>
<PHONE_2>+31 654661933</PHONE_2>
<FAX_1>+31 71 5248181</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7559" MODIFIED="2010-01-12 14:57:06 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Prof.</PREFIX>
<FIRST_NAME>John</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Guillebaud</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Family Planning &amp; Reproductive Health, Dept Gynaecology, University College London</POSITION>
<EMAIL_1>j.guillebaud@lineone.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Family Planning</DEPARTMENT>
<ORGANISATION>Margaret Pyke Family Planning Centre</ORGANISATION>
<ADDRESS_1>73 Charlotte Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>W1P 1LB</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+44 171 5303620</PHONE_1>
<PHONE_2/>
<FAX_1>+44 171 5303436</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="621085B682E26AA20125F76B43891F66" MODIFIED="2010-01-12 14:57:23 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Frances</FIRST_NAME>
<MIDDLE_INITIALS>M.</MIDDLE_INITIALS>
<LAST_NAME>Cowan</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>francesmcowan@yahoo.co.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Research Department of Infection &amp; Population Sciences</DEPARTMENT>
<ORGANISATION>University College London, Centre for Sexual Health&amp; HIV Research</ORGANISATION>
<ADDRESS_1>Gower Street</ADDRESS_1>
<ADDRESS_2/>
<CITY>London</CITY>
<ZIP>WC1E 6BT</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 263 912257949</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-01-12 15:50:39 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;New studies found and included or excluded: 11/16/03&lt;/p&gt;&lt;p&gt;Conclusions changed: 5/24/04&lt;/p&gt;" NOTES_MODIFIED="2010-01-12 15:50:39 +0100" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="15" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="15" MONTH="7" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="11" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;In 2009, two changes to the review methods were made from the original protocol. First, LILACS was added to the list of databases searched to identify studies. Second, the method for analysing contraception continuation rates was changed. The number of women months of continuation on each contraceptive method over the number of potential women months for each method was calculated at follow-up points (e.g. at one year) to provide a rate ratio. This method of analysis did not significantly change any findings from previous versions of this review.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Four additional studies were identified, three compared the LNG IUS with intrauterine devices (&lt;a link_type=&quot;STUDY&quot; href=&quot;Kapur 2008&quot; protected=&quot;true&quot;&gt;Kapur 2008&lt;/a&gt;, &lt;a link_type=&quot;STUDY&quot; href=&quot;Rogovskaya 2005&quot; protected=&quot;true&quot;&gt;Rogovskaya 2005&lt;/a&gt;, &lt;a link_type=&quot;STUDY&quot; href=&quot;Shaamash 2005&quot; protected=&quot;true&quot;&gt;Shaamash 2005&lt;/a&gt;) and one compared the LNG IUS with combined oral contraceptives (&lt;a link_type=&quot;STUDY&quot; href=&quot;Suhonen 2004&quot; protected=&quot;true&quot;&gt;Suhonen 2004&lt;/a&gt;). It was only possible to extract data from the &lt;a link_type=&quot;STUDY&quot; href=&quot;Suhonen 2004&quot; protected=&quot;true&quot;&gt;Suhonen 2004&lt;/a&gt; study. No pregnancies were reported in this study, but LNG IUS users were significantly more likely to report amenorrhoea, breast tenderness and acne after one year compared to combined oral contraceptive users.&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;Since the introduction of the LNG IUS and the inital publication of this review, few studies have been published employing rigourous methodologies, in line with CONSORT guidelines. &lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-11-11 11:11:27 +0100" NOTES_MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="7" YEAR="2009"/>
<DESCRIPTION>
<P>In 2009, three changes to the review methods were made from the original protocol. First, LILACS was added to the list of databases searched to identify studies. Second, the method for analysing contraception continuation rates was changed. The number of women months of continuation on each contraceptive method over the number of potential women months for each method was calculated at follow-up points (e.g. at one year) to provide a rate ratio. This method of analysis did not significantly change any findings from previous versions of this review. Finally, the terminology used to describe menstrual bleeding outcomes were changed to fit recommendations made by <LINK REF="REF-Fraser-2007" TYPE="REFERENCE">Fraser 2007</LINK>, for example "heavy menstrual bleeding" replaces "menorrhagia".</P>
<P>Four additional studies were identified, three compared the LNG IUS with intrauterine devices (<LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK>, <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>, <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>) and one compared the LNG IUS with combined oral contraceptives (<LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK>). It was only possible to extract data from the <LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK> study. No pregnancies were reported in this study, but LNG IUS users were significantly more likely to report an absence of menstrual bleeding, breast tenderness and acne after one year compared to combined oral contraceptive users.</P>
<P>The primary outcomes for this review are pregnancy and continutation rates. However, the new studies also offer important findings for breastfeeding women and diabetic women. The LNG-20 IUS did not impact upon breastfeeding performance or the development of breastfed infants in lactating women (<LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>) and LNG-20 IUS use had no adverse effect on glucose metabolism among insulin-dependent diabetics (<LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>).</P>
<P>Since the introduction of the LNG IUS and the inital publication of this review, few studies have been published employing rigourous methodologies, in line with CONSORT guidelines.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2009-10-05 17:02:30 +0200" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-09-25 12:47:45 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="15" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2009-10-05 17:02:30 +0200" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-09-30 17:17:21 +0200" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2009-09-30 17:17:21 +0200" MODIFIED_BY="[Empty name]">
<SOURCE>
<NAME>National Health Service Health Technology Assessment Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE MODIFIED="2009-09-30 17:17:21 +0200" MODIFIED_BY="[Empty name]">
<NAME>Department of Health Cochrane Review Incentive Scheme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>Funding was provided to update the review. </P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-01-12 15:45:01 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2010-01-03 19:11:55 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2009-11-10 19:04:00 +0100" MODIFIED_BY="[Empty name]">No difference found in pregnancy rates for women using either the LNG-20 intrauterine system (IUS) or intra-uterine device (IUD) for contraception</TITLE>
<SUMMARY_BODY MODIFIED="2010-01-03 19:11:55 +0100" MODIFIED_BY="[Empty name]">
<P>Reversible methods of contraception include the use of a system or device placed inside the uterus. The IUD is a copper device inserted into the uterus to prevent pregnancy. The intrauterine system (IUS) contains hormones that will be gradually released and provide effective contraception until removed.<BR/>
</P>
<P>The review of trials compared IUDs to IUSs and found there was no difference in the rate of unplanned pregnancies. The review found that a lack of menstrual bleeding is more likely with IUS use and that IUD use is more likely to cause heavy menstrual bleeding and pain.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-01-06 15:59:24 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-10-16 11:25:01 +0200" MODIFIED_BY="[Empty name]">
<P>Hormonally impregnated intrauterine systems (IUSs) add a progestogen to a non-medicated contraceptive device to improve contraceptive action.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-10-16 11:25:11 +0200" MODIFIED_BY="[Empty name]">
<P>To assess the contraceptive efficacy, tolerability and acceptability of IUSs versus other reversible contraceptive methods.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-10-16 11:25:33 +0200" MODIFIED_BY="[Empty name]">
<P>Searched databases, reference lists and relevant individuals/organisations covering the period from 1972 to July 2009.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-10-16 11:25:44 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) comparing IUSs with other reversible contraceptives and reporting on pre-determined outcomes, including pregnancy and continuation rates, in women of reproductive years.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-01-06 15:58:13 +0100" MODIFIED_BY="[Empty name]">
<P>Two blinded reviewers independently assessed quality and extracted data on events per women months and single decrement life table rates for pregnancy, continuation, adverse events and reasons for discontinuation. Events per total potential number of women at follow-up were collected for hormonal side effects and menstrual change.</P>
<P>Data were pooled at the same points of follow-up to calculate rate ratios and single decrement life table rate differences. Similar interventions were combined and non-hormonal intrauterine devices (IUDs) were divided into three categories: copper IUDs &gt;250mm<SUP>2</SUP>, copper IUDs &#8804;250mm<SUP>2</SUP>, and non-medicated IUDs.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-01-06 15:57:57 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-five RCTs met the inclusion criteria and nine were included in meta-analyses: four comparing LNG-20 IUSs (Mirena®) with non-hormonal IUDs, one with Norplant-2, one with combined oral contraceptives (COCs) and three comparing P4-IUS (Progestasert®) with non-hormonal IUDs.</P>
<P>No significant difference was observed between LNG-20 and IUD &gt;250mm<SUP>2</SUP> or COC user pregnancy rates.  LNG-20 IUS users were significantly less likely to become pregnant than IUD &#8804;250mm<SUP>2</SUP> users. LNG-20 IUS users were more likely to experience a lack of menstrual bleeding and device expulsion than IUDs &gt;250mm<SUP>2</SUP> users. LNG-20 users were significantly more likely than all IUD users to discontinue because of the lack of menstrual bleeding. They were significantly more likely to experience lack of and infrequent mentrual bleeding, but significantly less likely to experience prolonged bleeding and spotting than Norplant-2 users.</P>
<P>P4-IUS users were significantly less likely to become pregnant and more likely to discontinue than non-medicated IUD users, but no significant difference was observed for P4-IUS versus IUD &#8804;250mm<SUP>2</SUP> for these two outcomes. P4-IUS users were less likely to expel the device and more likely to discontinue because of menstrual bleeding and pain than IUDs &#8804;250mm<SUP>2</SUP> users.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-01-06 15:59:24 +0100" MODIFIED_BY="[Empty name]">
<P>Evidence suggests there is no difference in pregnancy rates among LNG-20 IUS, IUD &gt;250mm<SUP>2</SUP> and Norplant-2 users. The LNG-20 IUS more effectively prevented intrauterine and extrauterine pregnancies than IUDs &#8804;250mm<SUP>2</SUP>. P4-IUS was significantly more effective than non-medicated IUDs, but no difference was observed when compared to IUDs &#8804;250mm<SUP>2</SUP>. Continuation rates for LNG-20 IUS, non-hormonal IUDs and Norplant-2 were similar. Lack of menstrual bleeding was the main reason for discontinuation of LNG-20 IUS.</P>
<P>Recent evidence, from studies meeting the review inclusion criteria for the update conducted in July 2009, suggests that the LNG-20 IUS does not impact upon breastfeeding performance or the growth and development of breastfed infants in lactating women nor did the device have an adverse effect on glucose metabolism among insulin-dependent diabetic women.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-01-06 16:03:45 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2010-01-03 17:23:47 +0100" MODIFIED_BY="[Empty name]">
<P>In the 1970s a new approach to the delivery of hormonal contraception was researched and developed. It was suggested that the addition of a progestogen to a non-medicated contraceptive device improved its contraceptive action. An advantage of these hormonally impregnated intrauterine systems (IUS) is that they are relatively maintenance free, with users having to consciously discontinue using them to become pregnant rather than taking a proactive daily decision to avoid conception.</P>
<P>Levonorgestrel Intrauterine System<BR/>The levonorgestrel intrauterine system (LNG-IUS), Mirena®, is licensed for contraceptive use in over 100 countries and is used by over 12 million women worldwide (<LINK REF="REF-Bayer" TYPE="REFERENCE">Bayer</LINK>; <LINK REF="REF-FDA-2000" TYPE="REFERENCE">FDA 2000</LINK>). It has a T shaped plastic frame 32 mm long with a reservoir on the vertical stem of the IUS containing 52 mg of levonorgestrel mixed with polydimethylsiloxane. This allows a steady, local release of 20µg levonorgestrel per day. Insertion of the LNG-20 IUS may require local anaesthesia and dilatation of the cervical canal in nulliparous or peri-menopausal woman. The net ingredient cost of the LNG-20 IUS is more expensive than copper bearing IUDs, however it offers non-contraceptive benefits particularly in women with heavy menstrual bleeding and may offer an alternative to hysterectomy (<LINK REF="REF-Bayer-2009" TYPE="REFERENCE">Bayer 2009</LINK>; <LINK REF="REF-Hurskainen-2004" TYPE="REFERENCE">Hurskainen 2004</LINK>; <LINK REF="REF-Lahteenmaki-1998" TYPE="REFERENCE">Lahteenmaki 1998</LINK>).</P>
<P>Progesterone intrauterine system<BR/>The first IUS to be marketed was progesterone intrauterine system (P4-IUS), Progestasert®. It has a plastic T shaped frame with a 32 mm horizontal cross bar and a 36 mm vertical stem. The vertical stem holds 38 mg of progesterone within a silicone base and when it is placed within the uterus will release 65 mcg of progesterone per day. Its contraceptive action lasts for 12-18 months (<LINK REF="REF-Barnhart-1985" TYPE="REFERENCE">Barnhart 1985</LINK>) and is achieved by the endometrial suppression preventing implantation. A second mechanism involves the thickening of the cervical mucus preventing sperm penetration. Ovulation, however, is not affected with normal hormonal cyclical patterns demonstrated in users.</P>
<P>The license has not been renewed by the company in some countries in light of its reported disadvantages. These included:<BR/>- yearly reinsertions with the associated risk of pelvic inflammatory disease;<BR/>- increased ectopic pregnancy rate when compared to copper bearing devices;<BR/>- some women experiencing persistent menstrual spotting.</P>
<P>Measuring contraceptive effectiveness<BR/>Extensive reviews have helped to provide greater clarity in the understanding of the various methods and terminologies employed to measure contraceptive effectiveness and have examined their relative advantages and disadvantages (<LINK REF="REF-Trussell-1991" TYPE="REFERENCE">Trussell 1991</LINK>; <LINK REF="REF-Farley-1986" TYPE="REFERENCE">Farley 1986</LINK>). In brief, there are generally two methods which have been adopted, the Pearl Index (PI) and life-tables. The PI, the older method (<LINK REF="REF-Pearl-1933" TYPE="REFERENCE">Pearl 1933</LINK>), provides a rate per women years and is calculated by dividing the number of events (such as the number of women who discontinue using a contraceptive method) by the total number of women months and multiplying by 1200 (or 1300 if measurement is calculated by menstrual cycle). This method has been criticised because it does not account for the variation in risk of outcomes over time, nor does it account for the variation in loss to follow up (<LINK REF="REF-Potter-1966" TYPE="REFERENCE">Potter 1966</LINK>; <LINK REF="REF-Higgins-1985" TYPE="REFERENCE">Higgins 1985</LINK>). Life tables do account for these factors and are therefore the most appropriate way to report contraceptive data. Confusion arises because inconsistent methods are used to define and calculate these probabilities. In brief, multiple-decrement life table probabilities (also known as net, competing or crude rates) are calculated by working out the monthly probability of reasons for discontinuation, such as pregnancy or hormonal side effects, and multiplying these to establish the probability of discontinuation over a fixed period of time, i.e. at six months follow up, a year follow up, etc. However, single decrement life table probabilities (also known as gross, noncompeting or net rates) are recommended. They are calculated the same way but only for a single reason i.e. they censor women who discontinue a method for reasons other than the one being measured. Unfortunately, it is often impossible to distinguish which method has been used if it is not clearly stated by the authors as 'net' can be refering to single or multiple decrement probabilities.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-11-09 16:52:36 +0100" MODIFIED_BY="[Empty name]">
<P>To determine the contraceptive effectiveness, acceptability and tolerability of IUSs. In order to do this the following questions were asked:</P>
<P>1. What is the relative effectiveness of IUSs in comparison to other reversible contraceptive methods?<BR/>2. What is the relative acceptability of IUSs in comparison to other reversible contraceptive methods?<BR/>3. What is the relative tolerability of IUSs in comparison to other reversible contraceptive methods?<BR/>4. What is the relative effectiveness of different types of IUS?<BR/>5. What is the relative acceptability of different types of IUS?<BR/>6. What is the relative tolerability of different types of IUS?</P>
</OBJECTIVES>
<METHODS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-11-09 16:58:46 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomised controlled trial and controlled clinical (i.e. quasi-randomised) trial comparisons of hormonally impregnated IUSs with other forms of reversible contraceptives.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Women of reproductive years</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Hormonally impregnated IUSs versus: <BR/> non-hormonal IUDs<BR/> barrier contraceptives<BR/> oral contraceptives<BR/> injectable contraceptives<BR/> subdermal implants</P>
<P>Comparisons of different IUSs</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-11-09 16:58:46 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome measures<BR/>Pregnancy due to method/user failure at 1, 2, 3, 4 and 5 years after starting contraceptive method<BR/>Continuation of contraceptive method after 1, 2, 3, 4 and 5 years</P>
<P>Secondary outcome measures<BR/>Planned pregnancy after discontinuation of contraceptive method at 1 and 2 years<BR/>Failed removal</P>
<P>Hormonal side effects:<BR/>Headaches<BR/>Pelvic pain<BR/>Breast tenderness<BR/>Acne<BR/>Weight gain<BR/>Nausea/vomiting<BR/>Dizziness/vertigo<BR/>Hair growth<BR/>Hair loss<BR/>Ovarian cysts<BR/>Uterine cramps<BR/>Mood changes<BR/>Loss of libido</P>
<P>Menstrual bleeding changes (using termionology recommended by <LINK REF="REF-Fraser-2007" TYPE="REFERENCE">Fraser 2007</LINK>):<BR/>Painful menstruation<BR/>Spotting<BR/>Infrequent menstrual bleeding<BR/>Lack of menstrual bleeding<BR/>Heavy menstrual bleeding<BR/>Prolonged bleeding<BR/>Irregular bleeding</P>
<P>Local device problems:<BR/>Malposition<BR/>Translocation<BR/>Expulsion</P>
<P>Adverse clinical events:<BR/>Ectopic pregnancy<BR/>Pelvic inflammatory disease<BR/>Sexually transmitted infections<BR/>Anaemia<BR/>Breast cancer<BR/>Fibroids<BR/>Vaginitis<BR/>Urinary tract infection<BR/>Cervical intraepithelial neoplasia I<BR/>Cervical intraepithelial neoplasia II<BR/>Cervical intraepithelial neoplasia III<BR/>Invasive cervical cancer<BR/>Myocardial infarction<BR/>Stroke<BR/>Pulmonary embolism/thrombophlebitis<BR/>Gall bladder disease<BR/>Death</P>
<P>Reason for discontinuation:<BR/>Hormonal side effects<BR/>Menstrual change<BR/>Adverse clinical event<BR/>Local device problem<BR/>Planning pregnancy<BR/>Patient choice - other</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>We obtained relevant randomized and controlled clinical trials from a search of publications describing IUSs. We conducted computerized searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, POPLINE, LILACS and Web of Science using the following search strategy:</P>
<P>CENTRAL<BR/>intrauterine devices medicated</P>
<P>MEDLINE<BR/>intrauterine devices, medicated<BR/>AND<BR/>(clinical trial*)</P>
<P>EMBASE<BR/>1: intrauterine devices, medicated<BR/>2: intrauterine contraceptive device<BR/>3: IUS<BR/>4: 1 or 2 or 3<BR/>5: norgestrel<BR/>6: levonorgestrel<BR/>7: keto(w)desogestrel<BR/>8: etonorgestrel<BR/>9: P4-IUS or P4-IUS intrauterine progesterone contrac*<BR/>10: Mirena or Mirena coil or Mirena IUS<BR/>11: levonova<BR/>12: 5 or 6 or 7 or 8 or 9 or 10 or 11<BR/>13: 4 and 12</P>
<P>POPLINE<BR/>(kw) iud hormone releasing<BR/>AND<BR/>(subject or textword) clinical trial*</P>
<P>LILACS<BR/>intrauterine devices, medicated</P>
<P>In a previous version of this review the Science Citation Index and Psych. Lit. databases were searched from 1972 to 1998 July using the strategy:</P>
<P>#1 "INTRAUTERINE-DEVICES,-MEDICATED" / all subheadings<BR/>#2 INTRAUTERINE SYSTEM* or IUS*<BR/>#3 explode "NORGESTREL" / all subheadings<BR/>#4 "LEVONORGESTREL"/all subheadings<BR/>#5 NORGESTREL<BR/>#6 LEVONORGESTREL<BR/>#7 KETO near DESOGESTREL<BR/>#8 ETONORGESTREL<BR/>#9 P4-IUS<BR/>#10 MIRENA<BR/>#11 LEVONOVA<BR/>#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11</P>
<P>WEB OF SCIENCE (November 2003 - July 2009)</P>
<P>#1 "INTRAUTERINE-DEVICES,-MEDICATED" / all subheadings<BR/>#2 INTRAUTERINE SYSTEM* or IUS*<BR/>#3 explode "NORGESTREL" / all subheadings<BR/>#4 "LEVONORGESTREL"/all subheadings<BR/>#5 NORGESTREL<BR/>#6 LEVONORGESTREL<BR/>#7 KETO near DESOGESTREL<BR/>#8 ETONORGESTREL<BR/>#9 P4-IUS<BR/>#10 MIRENA<BR/>#11 LEVONOVA<BR/>#12 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11</P>
<P>The reference lists of all identified publications were searched for previously unidentified articles.</P>
<P>We contacted the relevant pharmaceutical companies and asked to release results of any relevant unpublished studies for inclusion in the review. Individuals and organisations with an interest in IUS research and databases housing information on clinical trials were solicited to identify unpublished and ongoing studies relevant to the review.</P>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>The selection of studies for inclusion and their methodological quality were independently assessed and reported by reviewers (RF, AS, FC and HV). Quality assessment forms were designed, and included general methodological factors, as well as some of contraceptive specific factors recommended by <LINK REF="REF-Trussell-1991" TYPE="REFERENCE">Trussell 1991</LINK>.The following quality factors were included on the checklist:<BR/>- method of randomization described,<BR/>- allocation concealment,<BR/>- blinded assessment of outcomes,<BR/>- groups treated identically other than named intervention,<BR/>- description of women who withdrew or were lost to follow up provided,<BR/>- description of hormonal contraceptive method or pregnancy immediately prior to study enrolment,<BR/>- statistical method (with reference) used to analyse pregnancy and continuation of methods,<BR/>- description of contraceptive failure provided (i.e. user or method failure or both),<BR/>- active follow up conducted (i.e. analysis of follow up delayed a few months to allow inclusion of undetected pregnancies)</P>
<SUBSECTION>
<HEADING LEVEL="4">Contraceptive effectiveness and continuation</HEADING>
<P>Single-decrement life table probabilities with their standard errors (SEs), and events per women months, akin to the Pearl Index rate, were collected for each outcome at specific follow up points (at one, two, three, four and five years). It was decided to collect both ways of reporting event rates as, although single-decrement rates are the ideal, they are not commonly employed and there was usually sufficient information in the papers to collect events per women months. Of those papers which had reported single decrement probabilities, only a few had given SEs, a necessity for meta-analysis. Authors who had used single decrement probabilities but had not given their SEs were contacted and asked to provide them where possible. Unless otherwise stated, in the rest of the text life table probabilities refers to single decrement life tables for any discontinuation outcomes.</P>
<P>In order to obtain a relative measure of continuation taking account of the time the method was used, the number of women months contributing to follow up and the number of potential women months at the specified time points were collected. Potential women months were calculated by multiplying the number of women recruited onto each of the studies with the total number of months at each of the specified time points (e.g. at one year the number of women recruited into a study was multiplied by 12 months). This method has been described as a way of measuring completeness to follow-up (<LINK REF="REF-Clark-2002" TYPE="REFERENCE">Clark 2002</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Menstrual changes, hormonal side-effects and adverse events</HEADING>
<P>Menstrual change outcomes were only collected if investigators had stipulated that they had been measured over 90 day intervals as recommended by <LINK REF="REF-Rodriguez-1976" TYPE="REFERENCE">Rodriguez 1976</LINK>. Lack of menstrual bleeding was no bleeding or spotting (B-S) throughout the reference period (RP). Infrequent bleeding was less than three B-S episodes starting within a RP excluding no menstrual bleeding; frequent bleeding was more than five B-S episodes starting within a RP; and prolonged bleeding was at least one B-S episode lasting greater than 14 days starting within a RP. The number of events and total number of women at each 90 day interval were collected to calculate risk ratios for menstrual change outcomes.</P>
<P>Data on hormonal side effects and planned pregnancy (after discontinuation of contraceptive method) were collected at yearly time intervals. Data on these outcomes were only collected if the investigators provided number of events and total number of women at follow up, so that risk ratios for each of the side effects identified in the protocol could be determined. Data on weight change were collected by extracting the mean weight difference, with its standard deviation, between the contraceptive methods under investigation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Data systhesis</HEADING>
<P>A description of the demographic characteristics of the study participants, the interventions, environmental and geographical factors which may influence findings, quality and the measured outcomes were collected, so that a decision could be made about the results of individual studies and whether it was feasible to combine the data.</P>
<P>Studies were only combined when the comparative interventions were similar, such as IUSs versus subdermal implants or IUSs versus non-hormonal IUDs contraceptives. Non-hormonal IUDs were divided into three categories for the purpose of data synthesis. The first, defined as IUDs &gt;250mm2, included CuT 380A and CuT 380Ag IUDs; the second, defined as IUDs &lt;=250mm2, included the Nova-T, Multiload, CuT 200 and CuT 220 IUDs; and the third were non-medicated IUDs. The first two categories were based on the surface area of the copper wire. In situations where it was not possible or appropriate to synthesise data, a narrative description is provided.</P>
<P>In order to obtain a summary effect size of an event per women months the rate ratios of the treatment and comparison events were combined. This method gave a relative measure of 'treatment' effect, that is how much more or less likely IUS users experienced an event in comparison to users of other contraceptive methods. The log rate ratios and their variances for events were calculated for each study (<LINK REF="REF-Hasselblad-1995" TYPE="REFERENCE">Hasselblad 1995</LINK>). It was then possible to calculate the inverse weighted average of the log rate ratios. Events were only combined if they were measured over the same time period (i.e. one year, two years and so on) because of their variability over time. For the purpose of data synthesis, in situations where there were no events in one arm of the trial a continuity correction was implemented by adding a half to each cell.</P>
<P>In order to synthesise life table probabilities, it was necessary to calculate the absolute measurement of 'treatment' effect. This was done by subtracting the comparison group probability from the intervention group probability. The SE for the measurement of true effect was then calculated by obtaining the square root of sum of the squared SE of the intervention group probability and the squared SE of the comparison group probability. If there was a probability of zero in one of the groups, its SE was assumed to be the same as the SE of the probability in the comparison group. The inverse weighted average of the rate differences was then calculated. It was thus possible to obtain an absolute difference in percentage terms of 'treatment' effect, that is the attributable risk, between IUS users and users of other contraceptive methods.</P>
<P>To order to obtain pooled estimates for risk ratios and mean differences, the inverse variance weighted average was used with the sample log risk ratio and the sample mean difference, respectively, calculated from each study (<LINK REF="REF-Petitti-1994" TYPE="REFERENCE">Petitti 1994</LINK>). A continuity correction was performed when necessary as described above for the calculated rate ratios.</P>
<P>Microsoft Excel was used to calculate the pooled effect sizes as it was not possible to calculate rate ratios or life table differences in RevMan.</P>
<P>The degree of heterogeneity was investigated and reported. A random effects approach was used for the meta-analysis (<LINK REF="REF-Dersimonian-1986" TYPE="REFERENCE">Dersimonian 1986</LINK>). In the absence of heterogeneity this coincides with a fixed effect analysis. No statistical heterogeneity was identified in the analyses unless explicitly stated in the results below.</P>
<P>An economic evaluation was conducted using the results of the systematic review and meta-analysis, and this has been published elsewhere (<LINK REF="REF-French-2000" TYPE="REFERENCE">French 2000</LINK>)</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-01-06 16:03:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-11-11 11:16:26 +0100" MODIFIED_BY="[Empty name]">
<P>Twenty-five RCTs comparing hormonally impregnated IUSs to a reversible contraceptive method met the inclusion criteria (See <LINK TAG="INCLUDED_STUDIES" TYPE="SECTION">Included studies</LINK>). Eleven trials were conducted in developing or transitional countries (<LINK REF="STD-Affandi-1980" TYPE="STUDY">Affandi 1980</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-Zhu-1991" TYPE="STUDY">Zhu 1991</LINK>) eight in developed countries (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Fylling-1979" TYPE="STUDY">Fylling 1979</LINK>; <LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Rybo-1983" TYPE="STUDY">Rybo 1983</LINK>; <LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK>) and five were international multicentre studies conducted in both developed and developing countries (<LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>;<LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>). In one publication it was not possible to determine the study setting (<LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>). The majority of trials (12) were set in community-based family planning clinics.</P>
<P>The age range of participants varied from 15 - 45 years. None of the studies confined entry to specific age requirements, other than ensuring the recruited women were of reproductive age. Seventeen of the 25 trials limited recruitment to women with proven fertility (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>;<LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>; <LINK REF="STD-Rybo-1983" TYPE="STUDY">Rybo 1983</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Zhu-1991" TYPE="STUDY">Zhu 1991</LINK>). Four studies recruited women post partum or post abortion (<LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>). Two studies restricted recruitment to women who were breast feeding (<LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>). Five studies stated that they only included women with regular menstrual cycles (<LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Zhu-1991" TYPE="STUDY">Zhu 1991</LINK>).</P>
<P>Nearly all of the interventions were either comparisons of IUSs with different hormonal release rates or of IUSs versus non-hormonal IUDs. There were two exceptions: a comparison of LNG-20 IUS with Norplant-2 (<LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>) and a comparison with combined oral contraceptives (<LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK>).</P>
<P>It was documented in two of the 21 trials that contraceptive counselling had been provided (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>). None of the studies mentioned any specific training for those inserting the devices.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-11-11 11:17:05 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the methodological quality of each of the studies are provided in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. It was documented that allocation of contraceptive method was concealed to the investigator in eleven trials (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK>; <LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>). It was reported that investigators were blind to contraceptive method when assessing outcomes in only four of the trials (<LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>). Women were blind to allocated method in an additional four studies (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>).</P>
<P>In 18 studies, the compared groups were treated identically in terms of measurement of outcomes (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Fylling-1979" TYPE="STUDY">Fylling 1979</LINK>;<LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK> <LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Rybo-1983" TYPE="STUDY">Rybo 1983</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>). A description of the characteristics of women lost to follow up or who withdrew from the study was not provided in any of the publications.</P>
<P>Twelve studies used life table analysis to determine pregnancy and continuation rates (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>). It was possible to determine whether single or multiple decrement probabilities had been reported in nine of these studies (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>) and all but one provided single decrement probabilities (<LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>).</P>
<P>Less than half of all studies provided information of contraceptive methods used or pregnancy immediately prior to enrolment (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>; <LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>). In the 15 studies where pregnancy occurred, nine distinguished between user or method failure (or both) (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>). Active follow up was conducted in three trials (<LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-01-06 16:03:45 +0100" MODIFIED_BY="[Empty name]">
<P>Some studies which would have met the inclusion criteria but examined prototype contraceptive methods or methods that are not (longer) available were excluded from the meta-analyses (<LINK REF="STD-El-Mahgoub-1982" TYPE="STUDY">El Mahgoub 1982</LINK>; <LINK REF="STD-Heikkila-1982" TYPE="STUDY">Heikkila 1982</LINK>; <LINK REF="STD-Janssen-2000" TYPE="STUDY">Janssen 2000</LINK>; <LINK REF="STD-Pakarinen-1996" TYPE="STUDY">Pakarinen 1996</LINK>; <LINK REF="STD-WHO-1983" TYPE="STUDY">WHO 1983</LINK>; <LINK REF="STD-WHO-1987" TYPE="STUDY">WHO 1987</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">LNG-20 versus non-hormonal IUD &gt;250mm2</HEADING>
<P>Five studies compared the LNG-20 IUS with the non-hormonal IUD &gt;250mm2 (<LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Kapur-2008" TYPE="STUDY">Kapur 2008</LINK>; <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>; <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>). It was possible to extract data from two of these studies for the meta analysis (<LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>). Rate ratios and single decrement life table differences derived from the two studies are presented in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> and <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK>, respectively (for the following outcomes: pregnancy, continuation, expulsion, embedded device, ectopic pregnancy, PID, and discontinuation due to hormonal side effects, menstrual side effects, adverse events, planning a pregnancy and/or personal choice). The relative risk for planned pregnancy after removal of the LNG-20 IUS compared to CuT 380 Ag IUD was 1.25 (95% CI 0.45 to 3.48) at one year (<LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>) <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>. It was possible to extract data on menstrual change outcomes from one study only (<LINK REF="STD-Sivin-1994" TYPE="STUDY">Sivin 1994</LINK>). Data from this study indicated that women using LNG-20 IUSs were more likely to experience no menstrual bleeding than women using CuT 380Ag IUDs and this risk increased over time, at three months the risk ratio was 2.35 (95% CI 1.37 to 4.04) <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> which increased to 11.08 (95% CI 6.61 to 18.57) at three years follow up. No significant differences were noticed between LNG-20 IUS and CuT 380Ag IUDs in terms of prolonged bleeding, with risk ratios of 0.88 (95% CI 0.55 to1.39) at three months and 0.15 (95% CI 0.02 to1.10) at three years <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. It was not possible to extract data for any other menstrual change outcomes, but Sivin et al (1994) reported that LNG-20 IUS users were significantly less likely to experience painful menstruation.</P>
<P>In addition to the primary outcomes for this review, two trials, <LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK> and <LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK> also reported clinically important findings for LNG-20 IUS users with insulin-dependent diabetes and lactating users. The LNG-20 IUS demonstated no adverse effects to glucose metabolism at 6 weeks, 6 months and 12 months in diabetic women (<LINK REF="STD-Rogovskaya-2005" TYPE="STUDY">Rogovskaya 2005</LINK>). Among lactating women in the Shaamash et al sudy, there was no significant difference between the two groups with regard to breastfeeding performance and infant growth (<LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>).</P>
<P>No data were collected for hormonal side effects.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LNG-20 versus non-hormonal &#8804;250mm2 IUDs</HEADING>
<P>Four included studies compared the LNG-20 IUS with non-hormonal &#8804;250mm2 IUDs (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>; <LINK REF="STD-Zhu-1991" TYPE="STUDY">Zhu 1991</LINK>). Data could be extracted from three of these studies (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>; <LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>; <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>). The calculated rate ratios and single decrement life table differences are shown in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> and <LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>, respectively, for the following outcomes: unplanned pregnancy, continuation of method, adverse event outcomes and reasons for discontinuation. Unpublished data on discontinuation of the LNG-20 IUS compared to the Nova-T because of a lack of menstrual bleeding from <LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK> (provided by <LINK REF="REF-Leiras-Ltd-1999" TYPE="REFERENCE">Leiras Ltd 1999</LINK>) demonstrated a huge variation between the participating centres, ranging from a multiple decrement probability of 2.7% in Finland to 19.6% in Hungary. No significant differences were observed in the rate ratios for planned pregnancy after discontinuation of the LNG-20 IUS and the Nova-T IUD (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>). The rate ratios at one and two years were 1.24 (95 CI 0.67 to 2.29) and 1.29 (95% CI 0.67 to 2.46) <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>, respectively. It was not possible to extract any data on menstrual change outcomes that did not result in discontinuation. The <LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK> study was the only one where it was possible to extract any data on hormonal side effects. No significant differences were observed between the risk of hormonal side effects for women using the LNG-20 IUS compared to women using the Nova-T IUD. These data were collected at five year follow up. The reported side effects and their risk ratios were as follows: acne, 5.56 [95% CI 0.73 to 42.35]; headaches, 1.62 (95% CI 0.53 to 4.92) <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>; breast tenderness, 1.50 (95% CI 0.31 to 7.17); ovarian cysts 1.50 (95% CI 0.51 to 4.40) and nausea, 4.99 (95% CI 0.24 to 103.86). <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK> observed that women using the LNG-20 IUS were more likely to report an increase in headaches and acne than women using the Nova-T IUD, but it was not possible to extract these data for the meta-analysis. The life table differences indicate there were no significant differences between the expulsion rates of these two methods (<LINK REF="TBL-04" TYPE="TABLE">Table 4</LINK>). However, the rate ratios suggest that women using the LNG-20 IUS are significantly less likely to have an expulsion after two years of follow up (<LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>). As it is data from one study used to calculate the life table differences (<LINK REF="STD-Baveja-1989" TYPE="STUDY">Baveja 1989</LINK>) and data from two other studies used to calculate the summary rate ratios (<LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK>, <LINK REF="STD-Luukkainen-1986" TYPE="STUDY">Luukkainen 1986</LINK>), it is impossible to ascertain what effect the different methods of analysis have had on the results or whether it is in fact caused by differences in the shape of the different IUDs. <LINK REF="STD-Andersson-1994" TYPE="STUDY">Andersson 1994</LINK> found that LNG-20 IUS users were significantly less likely to experience PID, in particular younger women, but we were unable to use the data in the meta-analysis. No other data on adverse outcomes were collected.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LNG-20 versus stainless steel ring IUD</HEADING>
<P>One study comparing the LNG-20 IUS with a stainless steel ring IUD was included [<LINK REF="STD-Zhu-1989" TYPE="STUDY">Zhu 1989</LINK>]. However, data on bleeding could not be extracted from the report.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LNG-20 versus subdermal implants</HEADING>
<P>One study which compared users of the LNG-20 IUS with users of subdermal implants, Norplant-2, was identified (<LINK REF="STD-Wang-1992" TYPE="STUDY">Wang 1992</LINK>). The rate ratios calculated for pregnancy, continuation, expulsion, ovarian cysts, breast cancer, and discontinuation due to hormonal side effects, menstrual side effects, device problems and/or adverse events are presented in <LINK REF="TBL-05" TYPE="TABLE">Table 5</LINK>. There were significant differences found in the rates of reported menstrual change. LNG-20 IUS users were significantly more likely to experience no menstruation compared to Norplant-2 users. The risk ratios were 2.27 (95% CI 1.03 to 4.99) at one year follow up, 42.46 (95% CI 2.62 to 689) at two years' follow up and 2.65 (95% CI 0.53 to 13) at three years' follow up. They were also significantly more likely to experience infrequent mentrual bleeding, risk ratio 6.17 (95% CI 2.76 to 13.78) at two year follow up, although significant differences were not found at years' one and three follow up. LNG-20 IUS users were significantly less likely to experience spotting than Norplant-2 users, risk ratios 0.33 (95% CI 0.18 to 0.60) at one year, 0.18 (95% CI 0.07 to 0.5) at two years and 0.17 (95% CI 0.05 to 0.57) at three years, and significantly less likely to have prolonged bleeding, risk ratios 0.13 (95% CI 0.05 to 0.35) at one year, 0.17 (95% CI 0.06 to 0.46) at two years and 0.15 (95% CI 0.04 to 0.64) at three years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">LNG-20 versus combined oral contraceptive</HEADING>
<P>One RCT compared LNG-20 IUS with combined oral contraceptives (<LINK REF="STD-Suhonen-2004" TYPE="STUDY">Suhonen 2004</LINK>). The rate ratios were calculated for pregnancy, continuation, hormonal side effects (headache, pelvic pain, acne, weight gain, and mood changes), menstrual changes (painful menstruation and absence of menstrual bleeding), expulsion, and discontinuation due to hormonal side effects and pregnancy are presented in <LINK REF="TBL-06" TYPE="TABLE">Table 6</LINK>. No pregnancies were observed in either group. LNG-IUS users when compared to combined oral contraceptive users were signficantly more likely to report an absence of menstrual bleeding, risk ratio 8.00 (95% CI 3.24-19.75); breast tenderness, risk ratio 2.28 (95% CI 1.32-4.68); and acne, risk ratio 1.75 (95% CI 1.00-3.08) at one year.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">P4-IUS versus non-hormonal IUDs &lt;=250mm2</HEADING>
<P>Seven trials comparing P4-IUS with non-hormonal IUDs &#8804;250mm2 were were identified (<LINK REF="STD-Affandi-1980" TYPE="STUDY">Affandi 1980</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>; <LINK REF="STD-Fylling-1979" TYPE="STUDY">Fylling 1979</LINK>; <LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>; <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>; <LINK REF="STD-Rybo-1983" TYPE="STUDY">Rybo 1983</LINK>) and two of these provided data that could be included in the meta-analysis, one comparing P4-IUS with the Nova-T IUD (<LINK REF="STD-Fylling-1979" TYPE="STUDY">Fylling 1979</LINK>) and other with the CuT 200 IUD (<LINK REF="STD-Larsen-1981" TYPE="STUDY">Larsen 1981</LINK>). The reasons for exclusion of data from the meta-analyses was either because P4-IUS was compared to methods that are no longer or have never been licensed (<LINK REF="STD-Affandi-1980" TYPE="STUDY">Affandi 1980</LINK>; <LINK REF="STD-WHO-1988" TYPE="STUDY">WHO 1988</LINK>; <LINK REF="STD-Piazarro-1977" TYPE="STUDY">Piazarro 1977</LINK>) or it was not possible to extract data (<LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK>; <LINK REF="STD-Rybo-1983" TYPE="STUDY">Rybo 1983</LINK>) Both included trials ran for one year. The rate ratios for pregnancy, continuation of method, expulsion and ectopic pregnancy calculated for these studies are presented in <LINK REF="TBL-07" TYPE="TABLE">Table 7</LINK>. No data for any of these outcomes were included in the meta-analysis. <LINK REF="STD-Lavin-1983" TYPE="STUDY">Lavin 1983</LINK> reported that P4-IUS users were significantly more likely to experience intermenstrual spotting, but significantly less likely to experience painful menstruation.</P>
<P>One comparison of P4-IUS and non-medicated IUDs was included (<LINK REF="STD-Newton-1979" TYPE="STUDY">Newton 1979</LINK>) and women were followed up for one year. Rate ratios for pregnancy, expulsion, ectopic pregnancy, and discontinuation for a planned pregnancy or personal reasons calculated from this study are presented in <LINK REF="TBL-08" TYPE="TABLE">Table 8</LINK>. No data were included in the meta-analysis on menstrual change or hormonal side effect outcomes. No pregnancies were reported in either group at one year.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-01-06 15:55:07 +0100" MODIFIED_BY="[Empty name]">
<P>There was insufficient evidence to suggest a difference in the pregnancy rates between LNG-20 IUS users and IUD &gt;250mm2 users. The rate of pregnancy in LNG-20 IUS users was significantly lower than the rate in the IUD &#8804;250mm2 users. No pregnancies occured in the small study comparing LNG-20 IUS users with combined oral contraceptive users. P4-IUS was significantly better at preventing pregnancy than the non-medicated IUD after one year, but not when compared to copper IUDs &#8804;250mm2.</P>
<P>When interpreting these findings on contraceptive effectiveness consideration must be paid to the limitations of the data. First, in the main, comparisons were of contraceptive methods with similar default states rather than comparisons of IUSs with methods where user adherence is likely to be a factor in effectiveness. Second, very large numbers of women would need to be recruited into these trials where in general the contraceptive methods being compared are highly effective in preventing unwanted pregnancy. Failure to detect a significant difference in contraceptive effectiveness between methods may be due to the small number of women enrolled and followed up in the included studies. Third, although life tables have been recommended as the most appropriate way to analyse contraceptive effectiveness data, and many of the included studies employed this method, confusion arose because of the inconsistent way these methods were defined and calculated. This resulted in some studies being excluded from the meta-analysis. It was much easier to extract data on number of events and women months or years from papers to provide an estimate akin to the Pearl Index.</P>
<P>Although it is useful to know how many unwanted pregnancies a method prevents, this information is of little value without collecting data on outcomes which reflect the acceptability of a method. A method may be efficacious in terms of preventing unwanted pregnancy, but if the method is discontinued within a short period of time its value as a method of contraception is greatly reduced. The meta-analyses conducted for continuation at yearly follow ups showed variable results between the different comparisons.</P>
<P>Few data could be extracted on hormonal side effects and menstrual change. The one outcome that users of all types of IUSs were significantly more likely to experience was lack of menstrual bleeding. The fact that so little data were available was not necessarily because authors had not reported these outcomes, but was due to the ways these outcomes had been measured. For instance, some investigators reported a percentage of women experiencing an 'increase', 'decrease' and 'the same' as measurements for events, such as painful menstruation or headaches. This does not allow baseline patterns on risk factors, such as age and parity, to be taken account of in the analysis.</P>
<P>The evidence on LNG-20 IUS suggested that women using this method were significantly more likely to expel the device than IUD &gt;250mm2 users. It has been recommended that only health care workers who have received specialist training should insert and remove these methods in order to prevent local device problems. None of the studies reported whether or not health care workers had received specialist training, therefore we were not able to investigate the effect this had device expulsions.</P>
<P>Breastfeeding provides some protection against another pregnancy, but the return of fertility is unpredictable. Which contraceptive method to use while breastfeeding, and when to start using it, are complicated decisions. Choices of contraception may be limited due to concerns about the effects of hormonal contraceptives on the quality and quantity of breastmilk, and the effects on the baby. One study included in this review found that LNG-20 IUS does not impact upon breastfeeding or the growth and development of breastfed infants (<LINK REF="STD-Shaamash-2005" TYPE="STUDY">Shaamash 2005</LINK>). Findings from another review showed no adverse effect of combined oral contraceptives on infant growth (<LINK REF="REF-Truitt-2003" TYPE="REFERENCE">Truitt 2003</LINK>)</P>
<P>P4-IUS's license was not renewed in some countries because of concerns about increased risk of ectopic pregnancy when compared to copper bearing devices. Too few studies were eligible for inclusion in the meta-analysis for this risk to be accurately determined.</P>
<P>Discontinuation due menstrual changes per se is not an informative outcome as the LNG-20 and IUD &gt;250mm2 comparison illustrates. Women using LNG-20 IUSs discontinued due to an absence of menstrual bleeding, while IUD &gt;250mm2 users discontinued because of bleeding and pain. The reporting of discontinuation due to absence of menstrual bleeding, bleeding and pain must be collected separately to provide a true picture.</P>
<P>An additional issue when interpreting data on discontinuation of methods due to menstrual changes is consideration of the 'cultural' setting in which the trials were conducted. For example, women from different backgrounds, as well as providers, may view menstrual change differently, as illustrated by the unpublished data from the Andersson study (<LINK REF="REF-Leiras-Ltd-1999" TYPE="REFERENCE">Leiras Ltd 1999</LINK>). Women should be informed of these potential side effects prior to starting these methods. The absence of menstrual bleeding in users of the LNG-20 IUS is benign and is due to high concentrations of levonorgestrel in the endometrium, the end organ (<LINK REF="REF-Silverberg-1986" TYPE="REFERENCE">Silverberg 1986</LINK>). Therefore, if women (and providers) are informed it has no ill effect on their health (and for some with heavy menstrual bleeding it may have a positive effect), the acceptability of these methods may be improved.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-01-06 15:55:39 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-01-06 15:55:39 +0100" MODIFIED_BY="[Empty name]">
<P>We found no significant difference in the risk of unwanted pregnancy between the LNG-20 IUS and IUDs &gt;250mm2 or Norplant-2 although, given the very large numbers needed to provide adequate power to detect differences in uncommon events, this may reflect a lack of power in the included studies. We did find a lower risk of pregnancy when the LNG-20 IUS was compared to IUDs &#8804;250mm2.</P>
<P>Women using the LNG-20 IUS were more likely to experience an absence of menstrual bleeding and this event was a notable reason for discontinuation. The much higher net ingredient cost (i.e. the device cost) of the LNG-20 IUS when compared to IUDs, with no discernible benefit in terms of contraceptive effectiveness when compared to IUDs &gt;250mm2, may suggest that its use should be targeted at those women who are concerned about menstrual bleeding and pain with IUD use. All women who are considering a LNG-20 IUS should be informed of the possibility of an absence of menstrual bleeding. Women who are diabetic or early postpartum and lactating should not be restricted from using the IUS.</P>
<P>Two other Cochrane reviews have shown that the LNG-IUS is also an effective treatment for heavy menstrual bleeding (<LINK REF="REF-Marjoribanks-2006" TYPE="REFERENCE">Marjoribanks 2006</LINK>; <LINK REF="REF-Lethaby-2005" TYPE="REFERENCE">Lethaby 2005</LINK>).</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This systematic review highlighted the problems which arise because of inconsistent methods used to measure and report contraceptive effectiveness. Although we were not able to assess what impact these factors had on pooled data, standardised methods need to be encouraged. </P>
<P>It is vital that contraceptive effectiveness research is able to answer the queries and concerns of contraceptive users. Unfortunately, this has not been the case to date. Although rates of unplanned pregnancy, continuation and reasons for discontinuation of methods do provide information on acceptability and tolerability as well as effectiveness, many studies fail to report hormonal side effects and menstrual changes. Women's choice and acceptance of different methods is likely to be affected by acceptability, tolerability and availability of alternatives and the desire not to conceive. If lay contraceptive users are involved in research development, attention can be directed to answering questions of importance to consumers.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-01-12 15:45:01 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank David Hughes, Tanya Proctor and Carolyn Summerbell for their assistance in contributing to the original protocol and the drafting earlier versions of this review.</P>
<P>We would like to thank for the following individuals for their help with the original review. First, Ms. Betsy Anagnostelis for her input into the design of the search strategy and Ms. Mani Gollopalli at the Institute of Child Health, Ms. Rita Ward at the International Planned Parenthood Federation and the fpa for their assistance in locating articles. The following have assisted in trying to locate unpublished data and provided general advice: Ms. Walli Bounds (Margaret Pyke Family Planning Centre), Dr. Irvin Sivin (The Population Council), Dr. Patrick Rowe (World Health Organization), Dr. Catherine d'Arcangues (World Health Organization), Dr. Régine Sitruk-Ware (Laboratoire Théramex), Ms. Toni Belfield (fpa), Sir Iain Chalmers (James Lind Library) and Hoechst Marion Roussel Ltd. We would like to acknowledge the following for their help with the translation of papers: Dr. Kevin Fenton (Spanish and Portuguese), Dr. Yu Yi (Chinese), and Mr. Patrick Austin (Danish and Swedish). Dr. Julian Higgins has provided much support and advice with the methodological aspects of conducting the meta-analyses. This work was funded by the National Health Service (NHS) Health Technology Assessment Programme.</P>
<P>In terms of the updated reviews, we wish to thank Carol Manion of Family Health International (North Carolina, US), who assisted with the literature searches. Funding for the 2009 update was provided by the Department of Health Cochrane Review Incentive Scheme, London, UK.</P>
<P>Finally, we would like to acknowledge the great support and encouragement received the Cochrane Fertility Regulation Review Group over the years, in particular Anja Helmerhorst.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-09-21 16:31:26 +0200" MODIFIED_BY="[Empty name]">
<P>Rebecca French: Reviewer<BR/>Annik Sorhaindo: Reviewer updated version<BR/>Frances Cowan: Reviewer and supervisor<BR/>John Guillebaud: Contraceptive advisor<BR/>Diana Mansour: Contraceptive advisor<BR/>Angela Robinson: Contraceptive advisor<BR/>Steve Morris: Health economist<BR/>Stuart Logan: Systematic review methodology advisor<BR/>Huib Van Vliet: Reviewer updated version<BR/>Frans Helmerhorst: Reviewer updated version</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-01-12 15:03:07 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-11-10 20:38:33 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-11-10 20:38:33 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Affandi-1980" MODIFIED="2009-11-10 20:32:59 +0100" MODIFIED_BY="[Empty name]" NAME="Affandi 1980" YEAR="1990">
<REFERENCE MODIFIED="2009-11-10 20:32:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Affandi B, Moeloek FA, Saifuddin AB, Sumapraja S. Comparative study between IUDs: Lippes Loop, Cu T-200, Cu-7, and Progestasert. [Abstract]. Contraceptive Delivery Systems. 1980;1:193.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 20:32:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Affandi B, Moeloek FA, Saifuddin AB, Sumapraja S</AU>
<TI>Comparative study between IUDs: Lippes Loop, Cu T-200, Cu-7, and Progestasert [Abstract]</TI>
<SO>Contraceptive Delivery Systems. Conference</SO>
<YR>1980</YR>
<VL>1</VL>
<PG>193</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andersson-1994" MODIFIED="2009-11-09 17:42:24 +0100" MODIFIED_BY="[Empty name]" NAME="Andersson 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-11-05 18:35:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersson K, Batar I, Rybo G</AU>
<TI>Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T</TI>
<SO>Contraception</SO>
<YR>1992</YR>
<VL>46</VL>
<PG>575-584</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andersson K, Odlind V, Rybo G</AU>
<TI>Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial</TI>
<SO>Contraception</SO>
<YR>1994</YR>
<VL>49</VL>
<PG>56-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lahteenmaki P, Shain RN, Ratsula K, et al</AU>
<TI>[One year experience of levonorgestrel-releasing intrauterine device] Ensimmaisen vuoden kokemukset levonorgestreeliehkaisimesta</TI>
<SO>Duodecim</SO>
<YR>1991</YR>
<VL>107</VL>
<PG>26-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luukkainen T, Allonen H, Haukkamaa M, et al</AU>
<TI>Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study</TI>
<SO>Contraception</SO>
<YR>1987</YR>
<VL>36</VL>
<PG>169-179</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-09 17:41:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rybo G, Andersson K, Odlind V</AU>
<TI>Hormonal intrauterine devices</TI>
<SO>Annals of Medicine</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>143-147</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-09 17:42:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Toivonen J, Luukkainen T, Allonen H</AU>
<TI>Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>1991</YR>
<VL>77</VL>
<PG>261-264</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baveja-1989" NAME="Baveja 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baveja R, Bichille LK, Coyaji KJ, et al</AU>
<TI>Randomized clinical trial with intrauterine devices (levonorgestrel intrauterine device (LNG), CuT 380Ag, CuT 220C and CuT 200B). A 36-month study. Indian Council of Medical Research Task Force on IUD</TI>
<SO>Contraception</SO>
<YR>1989</YR>
<VL>39</VL>
<PG>37-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Datey S, Gaur LN, Saxena BN</AU>
<TI>Vaginal bleeding patterns of women using different contraceptive methods (implants, injectables, IUDs, oral pills)- an Indian Experience</TI>
<SO>Contraception</SO>
<YR>1995</YR>
<VL>51</VL>
<PG>155-165</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-El-Mahgoub-1982" MODIFIED="2009-11-05 18:55:38 +0100" MODIFIED_BY="[Empty name]" NAME="El Mahgoub 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;el Mahgoub S. Long-term intracervical contraception with a levonorgestrel device. Contraception 1982;25:357-374.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Mahgoub S</AU>
<TI>Long-term intracervical contraception with a levonorgestrel device</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>357-374</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;el Mahgoub S. The norgestrel-T-IUD. Contraception 1980;22:271-286&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>El Mahgoub S</AU>
<TI>The norgestrel-T-IUD</TI>
<SO>Contraception</SO>
<YR>1980</YR>
<VL>22</VL>
<PG>271-286</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-05 18:55:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>El Mahgoub</AU>
<TI>Levonorgestrel releasing contraceptive devices</TI>
<SO>Long-acting contraception. Papers presented at the symposium on long acting contraception, Alexandria. Egypt, November 3-4, 1984</SO>
<YR>1983</YR>
<PG>174-179</PG>
<ED>Goldsmith A, Toppozada M</ED>
<PB>Nothwestern University, Program for Applied Research in Fertility Regulation</PB>
<CY>Chicago, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fylling-1979" MODIFIED="2009-11-09 17:42:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fylling 1979" YEAR="1978">
<REFERENCE MODIFIED="2009-11-09 17:42:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fylling P, Fagerhol M</AU>
<TI>Experience with two different medicated intrauterine devices: a comparative study of the Progestasert and Nova-T</TI>
<SO>Fertility and Sterility</SO>
<YR>1979</YR>
<VL>31</VL>
<PG>138-141</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heikkila-1982" NAME="Heikkila 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heikkila M</AU>
<TI>Puerperal insertion of a copper-releasing and a levonorgestrel-releasing intrauterine contraceptive device</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>561-572</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Janssen-2000" MODIFIED="2009-11-09 17:42:52 +0100" MODIFIED_BY="[Empty name]" NAME="Janssen 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-11-09 17:42:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Janssen CAH, Scholten PC, Heintz PM</AU>
<TI>The effect of low-dose 3-keto-desogestrel added to a copper-releasing intrauterine contraceptive device on menstrual blood loss: a double-blind, dose-finding, placebo-controlled study</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2000</YR>
<VL>182</VL>
<NO>3</NO>
<PG>575-581</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kapur-2008" MODIFIED="2009-11-09 17:43:11 +0100" MODIFIED_BY="[Empty name]" NAME="Kapur 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-11-09 17:43:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kapur SCA, Kumar SCS</AU>
<TI>Contraceptive effectiveness of levonorgestrel releasing intrauterine system</TI>
<SO>Medical Journal of the Armed Forces India</SO>
<YR>2008</YR>
<VL>64</VL>
<PG>140-142</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Larsen-1981" MODIFIED="2009-11-10 20:32:46 +0100" MODIFIED_BY="[Empty name]" NAME="Larsen 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-11-10 20:32:46 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larsen S, Hansen MK, Jacobsen JC, Ladehoff P, Sorensen T, Westergaard JG</AU>
<TI>Comparison between two IUDs: Progestasert and CuT 200</TI>
<SO>Contraceptive Delivery Systems</SO>
<YR>1981</YR>
<VL>2</VL>
<PG>281-286</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Larsen S, Hansen MK, Jacobsen JC, Ladehoff P, Sorensen T, Westergaard JG. [Progestasert and copper-T. A prospective, randomized clinical study of 2 coil types] Progestasert og kobber-T. En prospektiv, randomiseret klinisk undersogelse af to spiraltyper. Ugeskr Laeger 1980;143:13-14.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Larsen S, Hansen MK, Jacobsen JC, Ladehoff P, Sorensen T, Westergaard JG</AU>
<TI>[Progestasert and copper-T. A prospective, randomized clinical study of 2 coil types] Progestasert og kobber-T. En prospektiv, randomiseret klinisk undersogelse af to spiraltyper</TI>
<SO>Ugeskr Laeger</SO>
<YR>1981</YR>
<VL>143</VL>
<PG>13-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lavin-1983" MODIFIED="2009-11-10 20:33:35 +0100" MODIFIED_BY="[Empty name]" NAME="Lavin 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-11-10 20:33:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Lavin P, Bravo C, Waszak C. Comparison of T Cu 200 and Progestasert IUDs. Contraceptive Delivery Systems 1983;4:143-147.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 20:33:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lavin P, Bravo C, Waszak C</AU>
<TI>Comparison of T Cu 200 and Progestasert IUDs</TI>
<SO>Contraceptive Delivery Systems</SO>
<YR>1983</YR>
<VL>4</VL>
<PG>143-147</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Luukkainen-1986" MODIFIED="2009-11-10 20:33:48 +0100" MODIFIED_BY="[Empty name]" NAME="Luukkainen 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Luukkainen T, Allonen H, Haukkamaa M, Lahteenmaki P, Nilsson CG, Toivonen J</AU>
<TI>Five years' experience with levonorgestrel-releasing IUDs</TI>
<SO>Contraception</SO>
<YR>1986</YR>
<VL>33</VL>
<PG>139-148</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 20:33:48 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson CG, Allonen H, Diaz J, Luukkainen T</AU>
<TI>Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study</TI>
<SO>Fertility and Sterility</SO>
<YR>1983</YR>
<VL>39</VL>
<PG>187-192</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson CG, Luukkainen T, Diaz J, Allonen H</AU>
<TI>Clinical performance of a new levonorgestrel-releasing intrauterine device. A randomized comparison with a nova-T-copper device</TI>
<SO>Contraception</SO>
<YR>1982</YR>
<VL>25</VL>
<PG>345-356</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson CG, Luukkainen T, Diaz J, Allonen H</AU>
<TI>Intrauterine contraception with levonorgestrel: a comparative randomised clinical performance study</TI>
<SO>Lancet</SO>
<YR>1981</YR>
<VL>1</VL>
<PG>577-580</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Newton-1979" NAME="Newton 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Newton J, Szontagh F, Lebech P, Rowe P</AU>
<TI>A collaborative study of the progesterone intrauterine device (Progestasert). The World Health Organization Task Force on Methods for the Regulation of Implantation</TI>
<SO>Contraception</SO>
<YR>1979</YR>
<VL>19</VL>
<PG>575-589</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakarinen-1996" NAME="Pakarinen 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pakarinen P, Luukkainen T, Elomaa K, et al</AU>
<TI>A 12-month comparative clinical investigation of a levonorgestrel-releasing intracervical device situated in the uterine cavity or cervical canal</TI>
<SO>Contraception</SO>
<YR>1996</YR>
<VL>54</VL>
<PG>187-192</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakarinen-2003" MODIFIED="2009-09-16 15:56:42 +0200" MODIFIED_BY="[Empty name]" NAME="Pakarinen 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-09-16 15:56:39 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Päivi Pakarinen, Juhani Toivonen, Tapani Luukkainen</AU>
<TI>Randomized comparison of levonorgestrel- and copper releasing intrauterine systems immediately after abortion, with 5 years' follow-up</TI>
<SO>Contraception</SO>
<YR>2003</YR>
<VL>68</VL>
<PG>31-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piazarro-1977" MODIFIED="2009-11-10 20:35:12 +0100" MODIFIED_BY="[Empty name]" NAME="Piazarro 1977" YEAR="1977">
<REFERENCE MODIFIED="2009-11-10 20:35:12 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Pizarro E, Gomez R, Rowe PJ, Lucero S. Comparative study of the Progesterone T (65 mcg daily) and Copper 7 IUD. Contraception. 1977:16:313-323.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 20:35:12 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pizarro E, Gomez R, Rowe PJ, Lucero S</AU>
<TI>Comparative study of the Progesterone T (65 mcg daily) and Copper 7 IUD</TI>
<SO>Contraception</SO>
<YR>1977</YR>
<VL>16</VL>
<PG>313-323</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pizarro E, Gomez Rogers C, Rowe PJ</AU>
<TI>A comparative study of the effect of the Progestasert TM and Gravigard IUDs on dysmenorrhoea</TI>
<SO>Contraception</SO>
<YR>1979</YR>
<VL>20</VL>
<PG>455-466</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pizarro Orchard E, Gomez Rogers C</AU>
<TI>Clinical evaluation of the progesterone T intrauterine device</TI>
<TO>Evaluacion clinica del dispositivo intrauterino "T de progesterona"</TO>
<SO>Rev Chil Obstet Ginecol</SO>
<YR>1980</YR>
<VL>45</VL>
<PG>87-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rogovskaya-2005" MODIFIED="2009-09-16 16:22:04 +0200" MODIFIED_BY="[Empty name]" NAME="Rogovskaya 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-16 16:22:04 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rogovskaya S, Rivera R, Grimes D, Chen PL, Bosny PL, Prilepskaya V and Kulakov V</AU>
<TI>Effect of a levonorgestrel intrauterine system on women with Type 1 diabetes: A randomized trial</TI>
<SO>Obstetrics and Gynecology</SO>
<YR>2005</YR>
<VL>105</VL>
<PG>811-815</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rybo-1983" MODIFIED="2009-11-10 20:37:26 +0100" MODIFIED_BY="[Empty name]" NAME="Rybo 1983" YEAR="1983">
<REFERENCE MODIFIED="2009-11-10 20:37:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rybo G, Bergqvist A</AU>
<TI>Comparison of menorrhagia with Progestasert and Cu-T-200</TI>
<SO>La Revue de Medecine</SO>
<YR>1983</YR>
<VL>24</VL>
<PG>1463-1469</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shaamash-2005" MODIFIED="2009-09-16 16:21:36 +0200" MODIFIED_BY="[Empty name]" NAME="Shaamash 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-09-16 16:21:36 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shaamash AH, Sayed GH, Hussien MM, Shaaban MM</AU>
<TI>A compartive study of the levonorgestrel-releasing intrauterine system Mirena® versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development</TI>
<SO>Contraception</SO>
<YR>2005</YR>
<VL>72</VL>
<PG>346-351</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sivin-1994" MODIFIED="2009-11-10 20:38:07 +0100" MODIFIED_BY="[Empty name]" NAME="Sivin 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Belhadj H, Sivin I, Diaz S, et al</AU>
<TI>Recovery of fertility after use of the levonorgestrel 20 mcg/d or Copper T 380 Ag intrauterine device</TI>
<SO>Contraception</SO>
<YR>1986</YR>
<VL>34</VL>
<PG>261-267</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivin I, Alvarez F, Diaz J, et al</AU>
<TI>Intrauterine contraception with copper and with levonorgestrel: a randomized study of the TCu 380Ag and levonorgestrel 20 mcg/day devices</TI>
<SO>Contraception</SO>
<YR>1984</YR>
<VL>30</VL>
<PG>443-456</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivin I, Stern J, Coutinho E, et al</AU>
<TI>Prolonged intrauterine contraception: a seven-year randomized study of the levonorgestrel 20 mcg/day (LNg 20) and the Copper T380 Ag IUDS</TI>
<SO>Contraception</SO>
<YR>1991</YR>
<VL>44</VL>
<PG>473-480</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivin I, Stern J, Diaz J, et al</AU>
<TI>Two years of intrauterine contraception with levonorgestrel and with copper: a randomized comparison of the TCu 380Ag and levonorgestrel 20 mcg/day devices</TI>
<SO>Contraception</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>245-255</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 20:38:07 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivin I, Stern J</AU>
<TI>Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR)</TI>
<SO>Fertility and Sterility</SO>
<YR>1994</YR>
<VL>61</VL>
<PG>70-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sivin I, el Mahgoub S, McCarthy T, et al</AU>
<TI>Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study</TI>
<SO>Contraception</SO>
<YR>1990</YR>
<VL>42</VL>
<PG>361-378</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suhonen-2004" MODIFIED="2009-09-16 16:21:11 +0200" MODIFIED_BY="[Empty name]" NAME="Suhonen 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-09-16 16:21:11 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I</AU>
<TI>Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study</TI>
<SO>Contraception</SO>
<YR>2004</YR>
<VL>69</VL>
<PG>407-412</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wang-1992" MODIFIED="2009-11-10 20:38:33 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gao J, Wang SL, Wu SC, Sun BL, Allonen H, Luukkainen T</AU>
<TI>Comparison of the clinical performance, contraceptive efficacy and acceptability of levonorgestrel-releasing IUD and Norplant-2 implants in China</TI>
<SO>Contraception</SO>
<YR>1990</YR>
<VL>41</VL>
<PG>485-494</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SL, Wu SC, Xin XM, Chen JH, Gao J</AU>
<TI>Three years' experience with levonorgestrel-releasing intrauterine device and Norplant-2 implants: a randomized comparative study</TI>
<SO>Adv Contracept</SO>
<YR>1992</YR>
<VL>8</VL>
<PG>105-114</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-11-10 20:38:33 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Wang SL. [Comparative study of norplant-2 and levonorgestrel-releasing intrauterine devices]. Chung Hua Fu Chan Ko Tsa Chih 1990;25:232-4,253.&lt;/p&gt;" NOTES_MODIFIED="2009-11-10 20:38:33 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wang SL</AU>
<TI>[Comparative study of Norplant-2 and levonorgestrel-releasing intrauterine devices]</TI>
<SO>Chung Hua Fu Chan Ko Tsa Chih</SO>
<YR>1990</YR>
<VL>25</VL>
<PG>232-253</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHO-1983" NAME="WHO 1983" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chompootaweep S, Reinprayoon D</AU>
<TI>A comparative clinical trial of Copper T 220 C and Alza T IPCS 52 intrauterine devices in Thai women</TI>
<SO>Contraception</SO>
<YR>1986</YR>
<VL>33</VL>
<PG>437-442</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>The Alza T IPCS 52, a longer acting progesterone IUD: safety and efficacy compared to the TCu22OC and multiload 250 in two randomized multicentre trials. The World Health Organization's special programme of research, development and research training in human reproduction. Task Force on intrauterine devices for fertility regulation</TI>
<SO>Clin Reprod Fertil</SO>
<YR>1983</YR>
<VL>2</VL>
<PG>113-128</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHO-1987" NAME="WHO 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization</AU>
<TI>Microdose intrauterine levonorgestrel for contraception. World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction: Task Force on Intrauterine Devices for Fertility Regulation</TI>
<SO>Contraception</SO>
<YR>1987</YR>
<VL>35</VL>
<PG>363-379</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-WHO-1988" MODIFIED="2009-11-09 17:43:32 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 1988" YEAR="1988">
<REFERENCE MODIFIED="2009-11-09 17:43:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization, Andrade A, Pizarro E, Shaw ST, Souza JP, Belsey EM, Rowe PJ</AU>
<TI>Consequences of uterine blood loss caused by various intrauterine contraceptive devices in South American women</TI>
<SO>Contraception</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>1-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1989" NAME="Zhu 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhu P, Luo H, Xu R, Cheng J, Wu S et al.</AU>
<TI>The effect of intrauterine devices, the stainless steel ring, the copper T220, and releasing levonorgestrel, on the bleeding profile and the morphological structure of the human endometrium: a comparative study of three IUDs</TI>
<SO>Contraception</SO>
<YR>1989</YR>
<VL>40</VL>
<PG>425-438</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-09-16 17:04:18 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrade-1998" NAME="Andrade 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Andrade ATL, Araujo DAC, Abranches ADAG, Andrade GN</AU>
<TI>An experience with the levonorgestrel intrauterine device</TI>
<TO>Experiencia com dispositivo intrauterino de levonorgestrel</TO>
<SO>Bol Centro Biol Reprod</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>51-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chan-2007" MODIFIED="2009-09-16 17:04:18 +0200" MODIFIED_BY="[Empty name]" NAME="Chan 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-09-16 17:04:14 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>SSC Chan, WH Tam, W Yeo, MMY Yu, DPS Ng, AWY Wong, WH Kwan, PM Yuen</AU>
<TI>A randomised controlled trial of prophylactic levonorgestrel intrauterine system in tamoxifen-treated women</TI>
<SO>International Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>114</VL>
<PG>1510-1515</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-1992" NAME="Diaz 1992" YEAR="1992">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Diaz J, Diaz M, Marchi NM, Petta CA, Faundes A</AU>
<TI>Clinical comparative prospective study between a levonorgestrel releasing IUD (Ng-20 IUD) and the T-Cu 380A, up to 5 years of use</TI>
<TO>Estudo clinico prospectivo comparando um DIU liberdor de levonorgestrel (DIU Ng 20) com o T-Cu 380A ate cinco anos de uso</TO>
<SO>J Bras Ginecol</SO>
<YR>1992</YR>
<VL>102</VL>
<PG>281-286</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Diaz-1993" NAME="Diaz 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;Diaz J, Faundes A, Diaz M, Marchi N. Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil. Contraception 1996;54:187-192.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Diaz J, Faundes A, Diaz M, Marchi N</AU>
<TI>Evaluation of the clinical performance of a levonorgestrel-releasing IUD, up to seven years of use, in Campinas, Brazil</TI>
<SO>Contraception</SO>
<YR>1993</YR>
<VL>47</VL>
<PG>169-175</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Faundes-1993" NAME="Faundes 1993" YEAR="1993">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Faundes A, Alvarez F, Diaz J</AU>
<TI>A Latin American experience with levonorgestrel IUD</TI>
<SO>Ann Med</SO>
<YR>1993</YR>
<VL>25</VL>
<PG>149-153</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1977" NAME="Nilsson 1977" YEAR="1977">
<REFERENCE NOTES="&lt;p&gt;Nilsson CG. Comparative quantification of menstrual blood loss with d-norgestrel releasing IUD and a Nova-T copper device. Contraception 1977:15:379-387.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson CG</AU>
<TI>Comparative quantification of menstrual blood loss with d-norgestrel releasing IUD and a Nova-T copper device</TI>
<SO>Contraception</SO>
<YR>1977</YR>
<VL>15</VL>
<PG>379-387</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nilsson-1986" NAME="Nilsson 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;Nilsson CG, Lahteenmaki PL, Luukkainen T, Robertson DN. Sustained intrauterine release of levonorgestrel over five years. Feril Steril 1986;45:805-807.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Nilsson CG, Lahteenmaki PL, Luukkainen T, Robertson DN</AU>
<TI>Sustained intrauterine release of levonorgestrel over five years</TI>
<SO>Fertil Steril</SO>
<YR>1986</YR>
<VL>45</VL>
<PG>805-807</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakarinen-1999" NAME="Pakarinen 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pakarinen P, Lahteenmaki P, Rutanen EM</AU>
<TI>The effect of intrauterine and oral levonorgestrel administration on serum concentrations of sex hormone-binding globulin, insulin, and insulin-like growth factor binding protein-1</TI>
<SO>Acta Obstet Gynecol Scand</SO>
<YR>1999</YR>
<VL>78</VL>
<PG>423-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pedron-Neueo-1992" NAME="Pedron Neueo 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Pedron Neueo N. [Quantification of menstrual bleeding in women using intrauterine devices (IUDs)] Gaceta Medica de Mexico 1992;128:597-604.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pedron Neueo N</AU>
<TI>Quantification of menstrual bleeding in women using intrauterine devices (IUDs)</TI>
<SO>Gaceta Medica de Mexico</SO>
<YR>1992</YR>
<VL>128</VL>
<PG>597-604</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Skrzypulec-2008" MODIFIED="2009-09-16 16:43:15 +0200" MODIFIED_BY="[Empty name]" NAME="Skrzypulec 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-16 16:43:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Violetta Skrzypulec and Agnieszka Drosdzol</AU>
<TI>Evaluation of quality of life and sexual functioning of women using levonorgestrel-releasing intrauterine contraceptive system - Mirena</TI>
<SO>Collegium Antropologicum</SO>
<YR>2008</YR>
<VL>4</VL>
<PG>1059-1068</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trinh-2008" MODIFIED="2009-09-16 16:20:40 +0200" MODIFIED_BY="[Empty name]" NAME="Trinh 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-09-16 16:20:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xuan Bich Trinh, Wiebren A A Tjalma, Amin P. Makar, Guy Buytaert, Joost Weyler, Peter van Dam</AU>
<TI>Use of the levonorgestrel-releasing intrauterine system in breast cancer patients</TI>
<SO>Contraception</SO>
<YR>2008</YR>
<VL>90</VL>
<NO>1</NO>
<PG>17-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ulstein-1987" NAME="Ulstein 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ulstein M, Steier AJ, Hofstad T, Digranes A, Sandvei R</AU>
<TI>Microflora of cervical and vaginal secretion in women using copper- and norgestrel-releasing IUCDs</TI>
<SO>Acta Obstet Gynecol Scand</SO>
<YR>1987</YR>
<VL>66</VL>
<PG>321-322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yin-1993" NAME="Yin 1993" YEAR="">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Yin M, Zhu P, Luo H, Xu R</AU>
<TI>The presence of mast cells in the human endometrium pre- and post-insertion of intrauterine devices</TI>
<SO>Contraception</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>245-254</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhu-1991" NAME="Zhu 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zhu P, Luo H, Shi W, Wang J, Cheng J, Xu R</AU>
<TI>Observation of the activity of factor VIII in the endometrium of women pre- and post insertion of three types of IUDs</TI>
<SO>Contraception</SO>
<YR>1991</YR>
<VL>44</VL>
<NO>4</NO>
<PG>367-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2009-09-16 15:57:56 +0200" MODIFIED_BY="[Empty name]"/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-01-12 15:03:07 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-01-12 15:03:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Barnhart-1985" MODIFIED="2009-09-25 12:32:42 +0200" MODIFIED_BY="[Empty name]" NAME="Barnhart 1985" TYPE="OTHER">
<AU>Barnhart, editor</AU>
<TI>Alza Corporation: Progestasert</TI>
<SO>Oradell: Medical Economics Company, Inc</SO>
<PG>590-592</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bayer" MODIFIED="2010-01-03 17:19:39 +0100" MODIFIED_BY="[Empty name]" NAME="Bayer" TYPE="OTHER">
<AU>Bayer Health Care Limited</AU>
<TI>Trademarks and countries document</TI>
<SO>http://www.mirena.com/html/index.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bayer-2009" MODIFIED="2009-11-09 15:55:41 +0100" MODIFIED_BY="[Empty name]" NAME="Bayer 2009" TYPE="UNPUBLISHED">
<AU>Bayer (data on file)</AU>
<TI>FDA Approves News Indication for Mirena® to treat heavy menstrual bleeding in IUD users</TI>
<SO>http://pharma.bayer.com/scripts/pages/en/news_room/news_room/news_room83.php</SO>
<YR>Accessed 6th November, 2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clark-2002" MODIFIED="2009-09-16 17:23:41 +0200" MODIFIED_BY="[Empty name]" NAME="Clark 2002" TYPE="JOURNAL_ARTICLE">
<AU>Clar TG, Altman DG, De Stavola BL</AU>
<TI>Quantification of the completeness for follow-up</TI>
<SO>The Lancet</SO>
<YR>2002</YR>
<VL>359</VL>
<PG>1309-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dersimonian-1986" NAME="Dersimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>Dersimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Control Clin Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farley-1986" NAME="Farley 1986" NOTES="&lt;p&gt;Farley TM. Life-table methods for contraceptive research. Statistics in Medicine. 1986;5:475-489.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Farley TM</AU>
<TI>Life-table methods for contraceptive research</TI>
<SO>Statistics in Medicine</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>475-489</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-FDA-2000" MODIFIED="2010-01-12 15:03:07 +0100" MODIFIED_BY="[Empty name]" NAME="FDA 2000" TYPE="OTHER">
<AU>FDA</AU>
<TI>website:accessdata.fda.gov</TI>
<SO>http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021225s027lbl.pdf</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fraser-2007" MODIFIED="2009-11-09 15:58:36 +0100" MODIFIED_BY="[Empty name]" NAME="Fraser 2007" TYPE="JOURNAL_ARTICLE">
<AU>Fraser IS, Critchley HOD, Munro MG, Broder M</AU>
<TI>A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding</TI>
<SO>Fertiity and Sterility</SO>
<YR>2007</YR>
<VL>87</VL>
<NO>3</NO>
<PG>466-476</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hasselblad-1995" NAME="Hasselblad 1995" TYPE="JOURNAL_ARTICLE">
<AU>Hasselblad V, McCrory DC</AU>
<TI>Meta-analytic Tools for Medical Decision Making: A Practical Guide</TI>
<SO>Medical Decision Making</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>81-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-1985" NAME="Higgins 1985" NOTES="&lt;p&gt;Higgins JE, Wilkens LR. Statistical comparisons of Pearl rates. am J Obstet Gynecol. 1985;151:656-659.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JE, Wilkens LR</AU>
<TI>Statistical comparisons of Pearl rates.</TI>
<SO>Am J Obstet Gynecol</SO>
<YR>1985</YR>
<VL>151</VL>
<PG>656-659</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hurskainen-2004" MODIFIED="2009-11-09 15:37:51 +0100" MODIFIED_BY="[Empty name]" NAME="Hurskainen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hurskainen R, Teperi J, Rissanen P, Aalto AM, Kivela A et al</AU>
<TI>Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2004</YR>
<VL>291</VL>
<PG>1456-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lahteenmaki-1998" MODIFIED="2009-11-10 20:04:29 +0100" MODIFIED_BY="[Empty name]" NAME="Lahteenmaki 1998" TYPE="JOURNAL_ARTICLE">
<AU>Lahteenmaki P, Haukkamaa M, Puolakka J, Riikonen U, Sainio S, Suvisaari J et al</AU>
<TI>Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy</TI>
<SO>British Medical Journal</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>1122-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Leiras-Ltd-1999" NAME="Leiras Ltd 1999" TYPE="CORRESPONDENCE">
<AU>Rauramo I</AU>
<SO>Leiras data. Personal Communication</SO>
<YR>7th July, 1999</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lethaby-2005" MODIFIED="2009-11-09 18:15:46 +0100" MODIFIED_BY="[Empty name]" NAME="Lethaby 2005" TYPE="COCHRANE_REVIEW">
<AU>Lethaby AE, Cooke I, Rees M</AU>
<TI>Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2009-11-09 18:15:46 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-09 18:15:46 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD002126.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Marjoribanks-2006" MODIFIED="2009-11-09 18:17:42 +0100" MODIFIED_BY="[Empty name]" NAME="Marjoribanks 2006" TYPE="COCHRANE_REVIEW">
<AU>Majoribanks J, Lethaby A, Farquhar C</AU>
<TI>Surgery versus medical therapy for heavy menstrual bleeding</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2006</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-11-09 18:17:42 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-11-09 18:17:42 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="0.1002/14651858.CD003855.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Pearl-1933" NAME="Pearl 1933" NOTES="&lt;p&gt;Pearl R. Factors in human fertility and their statistical evaluation. The Lancet. 1933;2:607-611.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Pearl R</AU>
<TI>Factors in human fertility and their statistical evaluation</TI>
<SO>Lancet</SO>
<YR>1933</YR>
<VL>2</VL>
<PG>607-611</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Petitti-1994" NAME="Petitti 1994" TYPE="BOOK">
<AU>Petitti DB</AU>
<SO>Meta-analysis, Decision Analysis and Cost-Effectiveness Analysis</SO>
<YR>1994</YR>
<PB>Oxford University Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Potter-1966" NAME="Potter 1966" NOTES="&lt;p&gt;Potter RG. Application of Life Table Techniques to Measurement of Contraceptive Effectiveness. Demography. 1966;3:2897-304.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Potter RG</AU>
<TI>Application of Life Table Techniques to Measurement of Contraceptive Effectiveness</TI>
<SO>Demography</SO>
<YR>1966</YR>
<VL>3</VL>
<PG>297-304</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rodriguez-1976" NAME="Rodriguez 1976" NOTES="&lt;p&gt;Rodriguez G, Faundes-Latham A, Atkinson L. An approach to the analyses of menstrual patterns in the critical evaluation of contraceptives. Studies in Family Planning. 1976;7:42-51.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Rodriguez G, Faundes-Latham A, Atkinson L</AU>
<TI>An approach to the analyses of menstrual patterns in the critical evaluation of contraceptives</TI>
<SO>Studies in Family Planning</SO>
<YR>1976</YR>
<VL>7</VL>
<PG>42-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverberg-1986" MODIFIED="2009-11-09 18:04:09 +0100" MODIFIED_BY="[Empty name]" NAME="Silverberg 1986" TYPE="JOURNAL_ARTICLE">
<AU>Silverberg SG, Haukkamaa M, Arko H, Nilsson CG, Luukainen T</AU>
<TI>Endometrial morphology during long-term use of levonorgestrel releasing intrauterine devices</TI>
<SO>Inetrnational Journal of Gynecological Pathology</SO>
<YR>1986</YR>
<VL>5</VL>
<PG>235-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Truitt-2003" MODIFIED="2009-11-10 19:43:45 +0100" MODIFIED_BY="[Empty name]" NAME="Truitt 2003" TYPE="JOURNAL_ARTICLE">
<AU>Truitt ST, Fraser AB, Grimes DA, Gallo MF, Schulz KF</AU>
<TI>Combined hormonal versus nonhormonal versus progestin-only contraception in lactation.</TI>
<SO>Cochrane Database of Systematic Revews</SO>
<YR>2003</YR>
<VL>Issue 2</VL>
<PG>CD003988</PG>
<IDENTIFIERS MODIFIED="2009-11-08 18:47:24 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Trussell-1991" NAME="Trussell 1991" NOTES="&lt;p&gt;Trussell J, Hatcher RA, Cates WJ, Stewart FH, Kost K. A guide to interpreting contraceptive efficacy studies. Obstet Gynecol. 1991;10:201-220.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Trussell J, Hatcher RA, Cates WJ, Stewart FH, Kost K</AU>
<TI>A guide to interpreting contraceptive efficacy studies</TI>
<SO>Obstet Gynecol</SO>
<YR>1991</YR>
<VL>10</VL>
<PG>201-220</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2010-01-03 17:21:31 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-French-2000" NAME="French 2000" TYPE="OTHER">
<AU>French RS, Cowan FM, Mansour DJA, Morris S, Proctor T, Hughes D, Robinson A, Guillebaud J</AU>
<TI>Implantable contraceptives (subdermal implants and hormonally impregnated intrauterine systems) versus other forms of reversible contraceptives: two systematic reviews to assess relative effectiveness, acceptability, tolerability and cost-effectiveness</TI>
<SO>Health Technology Assessment</SO>
<YR>2000</YR>
<VL>4</VL>
<NO>7</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Affandi-1980">
<CHAR_METHODS>
<P>Setting: Indonesia<BR/>697 women randomised<BR/>Follow up: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Not stated</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=72] vs. CuT 200, Cu 7 and Lippes loop IUDs [n=75, 75 and 75, respectively]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Reasons for discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract</P>
<P>Quality assessment not conducted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Andersson-1994">
<CHAR_METHODS>
<P>Setting: Multinational (Denmark, Finland, Hungary, Norway and Sweden), Family Planning Clinics (12)<BR/>2758 women randomised<BR/>Follow up: 5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-38 years<BR/>Parous<BR/>Not breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 IUS [n=1821] vs. Nova-T IUD [n=937]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Adverse events<BR/>Hormonal side effects<BR/>Pregnancy after discontinuation of method</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: Centrally prepared envelopes<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Mesurement: Groups treated identically<BR/>Method of analysis: Life tables (multiple and single decrement rates)<BR/>User/method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:11:37 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baveja-1989">
<CHAR_METHODS>
<P>Setting: India, Family Planning Clinics<BR/>2118 women randomised<BR/>Follow up: 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-40 years<BR/>Proven fertility<BR/>Regular menses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 IUS [n=475] vs. CuT 380Ag, CuT 220C and CuT 200B IUDs [n=434, 496 and 500, respectively]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:37 +0200" MODIFIED_BY="[Empty name]">
<P>Pregancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Menstrual change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Computed random numbers<BR/>Allocation concealment technique: Sealed envelopes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (single decrement rates)<BR/>User / method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 18:05:56 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-El-Mahgoub-1982">
<CHAR_METHODS>
<P>Setting: Egypt, Family Planning Clinics<BR/>300 women randomised<BR/>Follow up: 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 18:05:56 +0200" MODIFIED_BY="[Empty name]">
<P>15-40 years<BR/>Parous<BR/>Hormonal contraceptive users at enrolment and immediate post partum women excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-10 IUS and Norgestrel T (various doses) IUSs vs. CuT 200 IUD [n=100 in each group]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:41 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Menstrual change and blood loss<BR/>Endometrial and cervical cell changes</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Method of analysis: Life tables (method not stated)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fylling-1979">
<CHAR_METHODS>
<P>Setting: Denmark<BR/>326 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Mixed parity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=162] vs. Nova-T IUD [n=164]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Serum immunoglobin levels</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:11:44 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Heikkila-1982">
<CHAR_METHODS>
<P>Setting: Finland, Maternity Unit<BR/>80 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Postpartum<BR/>Amenorrhoeic<BR/>Breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-30 IUS[n=40] vs. Nova-T IUD [n=40]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:44 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Hormonal side effects<BR/>Menstrual change<BR/>LNG plasma concentration<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Method of analysis: Other<BR/>User / method failure reported: Not applicable</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Janssen-2000">
<CHAR_METHODS>
<P>Setting: The Netherlands, University Medical Centre<BR/>203 women randomised<BR/>Follow up: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-45 years<BR/>Variable parity<BR/>Regular menses<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Multiload Cu250 releasing different doses of 3-keto- desogestrel [n= 151] vs. Multiload Cu250 [n=51]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Menstrual blood loss<BR/>Hemoglobin, ferritin and 3-keto-desogestrel concentration<BR/>Bleeding pattern<BR/>Subjective complaints</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment: Randomisation technique: Computer generated randomization list.<BR/>Allocation concealment technique: No mention. <BR/>Double-blinded assessment of outcomes.<BR/>Description of prior contraceptive method / pregnancy not provided<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 15:48:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kapur-2008">
<CHAR_METHODS MODIFIED="2009-09-16 15:48:13 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: India</P>
<P>170 women randomised</P>
<P>Follow-up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 15:48:24 +0200" MODIFIED_BY="[Empty name]">
<P>26-35 years</P>
<P>Parous, desiring contraception</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-16 15:48:35 +0200" MODIFIED_BY="[Empty name]">
<P>LNG IUS [n=70] vs. Cu T 380 [n=70]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 15:48:41 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy</P>
<P>Menstrual change</P>
<P>Reasons for discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-16 15:48:55 +0200" MODIFIED_BY="[Empty name]">
<P>Quality assessment:<BR/>Randomisation technique: no mention<BR/>Allocation concealment technique: no mention<BR/>Women blinded to method<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Larsen-1981">
<CHAR_METHODS>
<P>Setting: Denmark<BR/>382 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>15-44 years<BR/>Variable parity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=196] vs. CuT 200 IUD [n=186]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Women blinded to method<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (multiple decrement rates)</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lavin-1983">
<CHAR_METHODS>
<P>Setting: Chile, Maternity Unit<BR/>400 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Postpartum</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=200] vs. CuT 200 IUD [n=200] - 100 inserted by hand and 100 inserted an inserter in each group</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:12:45 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Menstrual change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:11:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Luukkainen-1986">
<CHAR_METHODS>
<P>Setting: Finland and Brazil, Family Planning Clinics<BR/>484 women randomised<BR/>Follow up: 2 years (Brazil and Finland) and 5 years (Finland only)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-40 years<BR/>Proven fertility<BR/>Not breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 and LNG-30 IUSs [n=164 and 163, respectively] vs. Nova-T IUD [n=157]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:50 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Resaons for discontinuation<BR/>Hormonal side effects<BR/>Menstrual change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Random tables (permutations of nine numbers)<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Double-blinded assessment of outcomes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Pearl indices and life tables (multiple and single decrement rates)<BR/>User / method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Newton-1979">
<CHAR_METHODS>
<P>Setting: Clinics (4)<BR/>676 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Various parity</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=359] vs. inert IUD [n=317]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:52 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Menstrual change<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment: 'both types of device were externally identical'<BR/>Double-blinded assessment of outcomes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Pakarinen-1996">
<CHAR_METHODS>
<P>Setting: Finland, Family Planning Clinics<BR/>298 women randomised<BR/>Follow up: 1 year<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-43 years<BR/>Variable parity<BR/>Regular menses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 IUS [n=147] vs. LNG-20 ICD [n=151]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Hormonal side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Random number table with group allocation predetermined<BR/>Allocation concealment technique: Consecutively numbered opaque sealed envelopes opened just before IUS insertion<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (single decrement rates)<BR/>User / method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 16:10:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pakarinen-2003">
<CHAR_METHODS MODIFIED="2009-09-16 16:04:33 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Demark, Finland, Hungary, Norway, Sweden, family planning clinic </P>
<P>438 women randomised 2:1 as a segment of a larger trial of 3000</P>
<P>Follow-up: 1, 3 and 5 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 16:06:55 +0200" MODIFIED_BY="[Empty name]">
<P>post elective termination</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-16 16:03:22 +0200" MODIFIED_BY="[Empty name]">
<P>Mirena [n=305] vs. Nova T [n=133]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 16:08:12 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-16 16:10:21 +0200" MODIFIED_BY="[Empty name]">
<P>Quality assessment:<BR/>Randomisation technique: not mentioned<BR/>Allocation concealment: Sealed envelopes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other data<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:11:55 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Piazarro-1977">
<CHAR_METHODS>
<P>Setting: Chile, Family Planning Clinics<BR/>295 women randomised<BR/>Follow up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>17-40 years<BR/>Parous<BR/>Regular menses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Progesterone T IUS [n=146] vs. Cu 7 IUD [n=149]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:55 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Menstrual change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Computed tables<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy reported<BR/>Blinded assessment of outcomes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (method not stated)<BR/>User / method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-09 17:38:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rogovskaya-2005">
<CHAR_METHODS MODIFIED="2009-09-16 15:49:08 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Moscow Russia, Ob/Gyn outpatient department</P>
<P>60 women randomised</P>
<P>Follow-up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 15:49:12 +0200" MODIFIED_BY="[Empty name]">
<P>18-45, with controlled insulin-dependent diabetes mellitus</P>
<P>Parous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-16 15:49:40 +0200" MODIFIED_BY="[Empty name]">
<P>Levonorgestrel intrauterine system [n=26] vs. copper T 380A [n=28]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-09 17:38:13 +0100" MODIFIED_BY="[Empty name]">
<P>Continuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-16 15:49:58 +0200" MODIFIED_BY="[Empty name]">
<P>Quality assessment:<BR/>Randomisation technique: Computer generated random numbers<BR/>Allocation concealment technique: Sealed opaque envelopes opened in numerical order<BR/>Description of prior contraceptive method / pregnancy reported<BR/>Women blind to method<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rybo-1983">
<CHAR_METHODS>
<P>Setting: France<BR/>Follow up: &lt; 1 year<BR/>30 women randomised</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24-42 years<BR/>Multiparous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=13] vs. CuT 200 IUD [n=17]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:11:58 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Menstrual change and blood loss<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Other</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shaamash-2005">
<CHAR_METHODS MODIFIED="2009-09-16 15:50:08 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Egypt, Department of Obstetrics and Gynecology</P>
<P>320 women randomised</P>
<P>Follow-up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 15:50:29 +0200" MODIFIED_BY="[Empty name]">
<P>Parous</P>
<P>Exclusively breastfeeding for at least 1 year</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-16 15:50:31 +0200" MODIFIED_BY="[Empty name]">
<P>LNG-IUS [n=163] vs. Cu T380A IUD [n=157]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-11-09 17:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>Continuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>Quality assessment:<BR/>Randomisation technique: Computer generated sequential numbers<BR/>Allocation concealment: Sealed opaque envelopes opened in sequential orderMeasurement: Groups treated identically<BR/>Method of analysis:Other</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:12:03 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sivin-1994">
<CHAR_METHODS>
<P>Setting: Multinational (Singapore, Brazil, Egypt and USA), Family Planning Clinics<BR/>2226 women randomised<BR/>Follow up: 7 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18-38 years<BR/>Parous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 IUS [n=1125] vs. CuT 380Ag IUD [n=1121]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:12:03 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Insertion problems<BR/>Hormonal side effects<BR/>Menstrual change<BR/>Adverse events<BR/>Pregnancy after discontinuation of method</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Random numbers - blocks of 50<BR/>Allocation concealment: Sealed opaque envelopes opened in ascending numerical order<BR/>Women blinded to method<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (multiple and single decrement rates)<BR/>User / method failure reported<BR/>Active follow up conducted<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 15:33:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Suhonen-2004">
<CHAR_METHODS MODIFIED="2009-09-16 15:33:30 +0200" MODIFIED_BY="[Empty name]">
<P>Setting: Helsinki Finland, Family-planning clinics</P>
<P>200 women randomised</P>
<P>Follow-up: 1 year</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-09-16 15:33:32 +0200" MODIFIED_BY="[Empty name]">
<P>18-25 years</P>
<P>Nulliparous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-16 15:33:34 +0200" MODIFIED_BY="[Empty name]">
<P>LNG-IUS [n=94] vs. oral contraceptives [n=99]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 15:33:19 +0200" MODIFIED_BY="[Empty name]">
<P>Continuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-09-16 15:33:16 +0200" MODIFIED_BY="[Empty name]">
<P>Quality assessment:<BR/>Randomisation technique: No mention</P>
<P>Measurement: Groups treated identically<BR/>Method of analysis: Other<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-09-16 13:12:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wang-1992">
<CHAR_METHODS>
<P>Setting: China, Family Planning Clinics<BR/>200 women randomised<BR/>Follow up: 3 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20-40 years<BR/>Parous<BR/>Not breast feeding</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-20 IUS [n=100] vs. Norplant-2 [n=100]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-16 13:12:06 +0200" MODIFIED_BY="[Empty name]">
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation<BR/>Menstrual change</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Sequential identication number <BR/>Allocation concealment technique:<BR/>Sealed envelopes<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Meseasurement: Groups treated identically<BR/>Method of analysis: Life tables (single decrement rates)<BR/>User / method failure reported</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-WHO-1983">
<CHAR_METHODS>
<P>Multinational (13 countries), Family Planning Clinics<BR/>5542 women randomised (2514 birth spacing insertion and 3028 post abortion insertion)<BR/>Follow up: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16-40 years<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Alza T IPCS 52 [n=1254] vs. CuT 220C IUD [n=1260] - interval insertion<BR/>2. Alza T IPCS 52 [n=985] vs. CuT 220C and Multiload IUDs [n=1032 and 1011, respectively] - post abortion insertion</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Computed random tables <BR/>Allocation concealment technique: Sealed envelopes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (single decrement rates)<BR/>User / method failure reported<BR/>Active follow up conducted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-WHO-1987">
<CHAR_METHODS>
<P>Multinational (Thailand, China, India, Vietnam, Cuba, Russia, Yugloslavia and Zambia)<BR/>4182 women randomised<BR/>Follow up: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>16-40 years<BR/>Parous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-2 IUS [n=1377] vs. CuT 220C and Nova-T IUDS [n=1412 and 1393, respectively]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pregnancy<BR/>Continuation<BR/>Reasons for discontinuation</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: Computed tables<BR/>Allocation concealment technique: Sealed envelopes<BR/>Measurement: Groups treated identically<BR/>Method of analysis: Life tables (single decrement rates)<BR/>User / method failure reported<BR/>Active follow up conducted</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-WHO-1988">
<CHAR_METHODS>
<P>Setting: Chile and Brazil (see Notes), Hospital<BR/>150 women randomised<BR/>Follow up: 2 years</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Parous</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-03 16:59:40 +0100" MODIFIED_BY="[Empty name]">
<P>P4-IUS [n=49] vs. Lippes lopp and Cu 7 IUDs [n=51 and 50, respectively]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Menstrual blood loss<BR/>Iron status</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Brazil group excluded because not randomised</P>
<P>Quality assessment:<BR/>Randomisation technique: Random number table<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy provided<BR/>Method of analysis: Not applicable<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Zhu-1989">
<CHAR_METHODS>
<P>Setting: China, University Medical Center<BR/>96 women randomised<BR/>Folllow up: CuT220 and stainless steel ring: 2 years and LNG-IUS: 3-10 months</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>25 -35 years<BR/>Proven fertility<BR/>Regular menses</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>LNG-IUS [n=19] vs. CuT 220 [n=43] vs. stainless steel ring [n=34]</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Morphological structure of the endometrium<BR/>Number of bleeding days<BR/>Bleeding rate</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Quality assessment:<BR/>Randomisation technique: No mention<BR/>Allocation concealment technique: No mention<BR/>Description of prior contraceptive method / pregnancy not provided<BR/>Method of analysis: other<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-09-16 17:15:45 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Andrade-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS vs. CuT 380A IUD<BR/>We could not reach the authors for additional information on generation of allocation sequence<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-16 17:15:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-16 17:15:45 +0200" MODIFIED_BY="[Empty name]">
<P>Intervention: LNG-IUS vs. no method</P>
<P>Primary outcomes: <I>De novo </I>endometrial pathology at 1 year tamoxifen</P>
<P>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diaz-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS vs. CuT 380Ag IUD<BR/>We could not reach the authors for additional information<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Diaz-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS vs. CuT 380Ag IUD<BR/>Primary outcomes: Pregnancy, continuation and reasons for discontinuation<BR/>Only report outcomes for LNG-IUS users. Comparative results reported elsewhere (see Sivin 1994)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Faundes-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS vs. CuT 380Ag IUD<BR/>Primary outcomes: Pregnancy, continuation, reasons for discontinuation, ovarian function and LNG serum levels<BR/>Only report outcomes for LNG-users. Comparative results reported elsewhere (see Sivin 1994)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nilsson-1977">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: d-norgestrel releasing IUS vs. Nova-T 200 IUD<BR/>Primary outcomes: Menstrual blood loss<BR/>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nilsson-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNg-20 IUS vs. LNG-30 IUS<BR/>Primary outcomes: Plasma concentration of LNG<BR/>Reported outcomes not relevant to review (other publications of study included - see Luukkainen 1986)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pakarinen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS, NovaT380 and 30 mcg LNG oral contraceptive<BR/>Primary outcomes: glucose, insulin, SHBG, IGFBP-1, testosterone and LNG concentration<BR/>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pedron-Neueo-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: Various IUSs and IUDs (11)<BR/>Primary outcomes: Menstrual blood loss<BR/>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-16 16:45:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Skrzypulec-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-16 16:45:15 +0200" MODIFIED_BY="[Empty name]">
<P>Intervention: LNG-IUS, other IUD and no contraception</P>
<P>Primary outcome: Quality of life</P>
<P>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-16 16:24:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trinh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-16 16:24:53 +0200" MODIFIED_BY="[Empty name]">
<P>Intervention: LNG-IUS vs. no history of LNG-IUS use in breast cancer patients</P>
<P>Primary outcome: Breast cancer recurrence rate</P>
<P>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ulstein-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS vs. copper IUD<BR/>Primary outcomes: Changes in cervical and vaginal microflora<BR/>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Yin-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS, stainless steel ring and CuT 220 IUD<BR/>Primary outcomes: Endometrial mast cell density<BR/>Reported outcomes not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zhu-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Intervention: LNG-IUS, stainless steel ring and CuT 220 IUD<BR/>Primary outcome: factor VIII actvity in endometrium<BR/>Reported outcomes: not relevant to review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-09-16 15:57:56 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-11-10 19:28:52 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-11-10 19:28:52 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Affandi-1980">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Andersson-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Baveja-1989">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-El-Mahgoub-1982">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Fylling-1979">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Heikkila-1982">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Janssen-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 15:52:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kapur-2008">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Larsen-1981">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lavin-1983">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Luukkainen-1986">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Newton-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Pakarinen-1996">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-10-05 17:00:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pakarinen-2003">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Piazarro-1977">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 15:52:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rogovskaya-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Rybo-1983">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 15:52:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shaamash-2005">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sivin-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 15:52:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Suhonen-2004">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-WHO-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-WHO-1987">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-WHO-1988">
<DESCRIPTION>
<P>D - Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Wang-1992">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Zhu-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2009-09-16 15:35:34 +0200" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-11-11 11:11:27 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>LNG-20 versus IUD &gt;250mm2: Rate ratios with 95% CI</TITLE>
<TABLE COLS="6" ROWS="14">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>Two years</P>
</TH>
<TH>
<P>Three years</P>
</TH>
<TH>
<P>Four years</P>
</TH>
<TH>
<P>Five years</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
<P/>
</TD>
<TD>
<P>1.01 (0.71 - 5.82)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>0.30 (0.07 - 1.24)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>0.11 (0.01 - 2.12)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.66 (0.25 - 1.75)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuation</P>
</TD>
<TD>
<P>0.97 (0.90 - 1.06)<BR/>[Sivin 1994, Baveja 1989] </P>
</TD>
<TD>
<P>0.94 (0.86 - 1.04)<BR/>[Sivin 1994, Baveja 1989]</P>
</TD>
<TD>
<P>0.89 (0.71 - 1.11)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.91 (0.78 - 1.06)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>1.11 (0.72 - 1.71)<BR/>[Sivin 1994] </P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.53 (1.13 - 2.07)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Embedded</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>7.0 (0.36 - 135.52)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Ectopic<BR/>Pregnancy</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>None</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.22 (0.01 - 4.56)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>PID</P>
</TD>
<TD>
<P>1.23 (0.50 - 3.03)<BR/>[Sivin 1994] </P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Hormonal</P>
</TD>
<TD>
<P>0.81 (0.23 - 2.80)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.71 (0.64 - 4.55)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>4.24 (1.99 to 9.05)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>All Menstrual</P>
</TD>
<TD>
<P>1.48 (1.02 - 2.14)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.48 (1.23 - 1.79)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Bleeding<BR/>&amp; pain</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.71 (0.56 - 0.89)<BR/>[Sivin 1990]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Pain only</P>
</TD>
<TD>
<P>0.80 (0.41 - 1.56)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual: Absence of menstrual bleeding</P>
</TD>
<TD>
<P>65.51 (4.01 - 1069.85)<BR/>[Sivin 1994] </P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>48.92 (16.93 - 141.36)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Adverse event</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.03 (0.18 - 5.92)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Planning pregnancy</P>
</TD>
<TD>
<P>0.94 (0.47 - 1.89)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.11 (0.89 - 1.39)<BR/>[Sivin 1994]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2009-11-09 17:39:39 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>LNG-20 IUS versus IUD &gt;250mm2: Life table differences with 95%CI</TITLE>
<TABLE COLS="6" ROWS="12">
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>Two years</P>
</TH>
<TH>
<P>Three years</P>
</TH>
<TH>
<P>Four years</P>
</TH>
<TH>
<P>Five years</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>-0.16 (-0.65 to 0.34)<BR/>[Sivin 1994, Baveja 1989]</P>
</TD>
<TD>
<P>-1 (-2.39 to 0.39)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>-1 (-2.39 to 0.39)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>-0.3 (-1.56 to 0.96)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuation</P>
</TD>
<TD>
<P>-6.3 (-10.00 to -2.56)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>-8.1 (-12.40 to -3.80)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>-7.6 (-11.90 to -3.30)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>0.84 (-1.19 to 2.88)<BR/>[Sivin 1994, Baveja 1989]</P>
</TD>
<TD>
<P>2.1 (-1.64 to 5.84)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>3 (-1.17 to 7.17)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>4.4 (1.46 to 7.34)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>PID</P>
</TD>
<TD>
<P>0.3 (-0.96 to 1.56)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Hormonal</P>
</TD>
<TD>
<P>-0.1 (-1.21 to 1.01)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>All menstrual</P>
</TD>
<TD>
<P>6.91 (2.87 to 10.94)<BR/>[Sivin 1994, Baveja 1989]</P>
</TD>
<TD>
<P>11.1 (6.26 to 15.94)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>14.5 (8.78 to 20.22)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Bleeding<BR/>&amp; pain</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>-7.9 (-10.89 to -4.91)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Mentrual - Pain only</P>
</TD>
<TD>
<P>-0.9 (-2.86 to 1.06)</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Absence of menstrual bleeding</P>
</TD>
<TD>
<P>5.04 (3.19 to 6.90)<BR/>[Sivin 1994, Baveja 1989]</P>
</TD>
<TD>
<P>9.5 (6.27 to 12.73)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>13.3 (9.30 to 17.30)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>19.3 (16.14 to 22.46)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation: Planning pregnancy</P>
</TD>
<TD>
<P>-0.1 (-2.04 to 1.84)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.5 (-3.50 to 6.50)<BR/>[Sivin 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation: Personal choice</P>
</TD>
<TD>
<P>0.8 (-1.01 to 2.61)<BR/>[Sivin 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.1 (-3.50 to 3.70)<BR/>[Sivin 1994]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2009-11-09 17:40:06 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>LNG-20 IUS versus IUD &lt;=250mm2: Rate ratios with 95% CI</TITLE>
<TABLE COLS="6" ROWS="13">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>Two years</P>
</TH>
<TH>
<P>Three years</P>
</TH>
<TH>
<P>Four years</P>
</TH>
<TH>
<P>Five years</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>0.12 (0.03 - 0.49)<BR/>[Andersson 1994; Luukkainen 1986]<BR/>Evidence of heterogeneity</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.07 (0.02 - 0.19)<BR/>[Andersson 1994; Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.08 (0.04 - 0.18)<BR/>[Andersson 1994; Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuation</P>
</TD>
<TD>
<P>1.03 (0.96 - 1.11)<BR/>[Andersson 1994; Baveja 1989]<BR/>Evidence of heterogeneity</P>
</TD>
<TD>
<P>0.93 (0.80 - 1.07)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>0.98 (0.80 - 1.07)<BR/>[Andersson 1994; Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.04 (0.92 - 1.18)<BR/>[Andersson 1994; Luukkainen 1986]<BR/>Evidence of heterogeneity</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>0.71 (0.02 - 1.13)<BR/>[Andersson 1994]</P>
</TD>
<TD>
<P>0.11 (0.02 - 0.6)<BR/>[Luukkainen 1986]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.27 (0.06 - 1.13)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Ectopic<BR/>pregnancy</P>
</TD>
<TD>
<P>0.72 (0.07 - 6.91)<BR/>[Andersson 1994; Luukkainen 1986]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.1 (0.02 - 0.62)<BR/>[Andersson 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.07 (0.01 - 0.41)<BR/>[Andersson 1994]</P>
</TD>
</TR>
<TR>
<TD>
<P>PID</P>
</TD>
<TD>
<P>None<BR/>[Luukkaainen 1986]</P>
</TD>
<TD>
<P>0.4 (0.01 - 2.68)<BR/>[Luukkainen 1986]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Hormonal</P>
</TD>
<TD>
<P>5.40 (2.25 - 12.97)<BR/>[Andersson 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>3.05 (0.24 - 38.34)<BR/>[Andersson 1994; Baveja 1989]<BR/>Evidence of heterogeneity</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>5.18 (1.32 - 20.34)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>All Menstrual</P>
</TD>
<TD>
<P>1.18 (0.88 - 1.57)<BR/>[Andersson 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.17 (0.66 - 2.06)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontiuation:<BR/>Mentrual - Bleeding<BR/>&amp; pain</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.49 (0.24 - 1.01)<BR/>[Luukkainen 1986]<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Absence of menstrual bleeding</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>29.2 (1.75 - 488.04)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Adverse event</P>
</TD>
<TD>
<P>1.0 (0.59 - 1.68)<BR/>[Andersson 1994]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>1.14 (0.24 - 5.38)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.78 (0.25 - 2.44)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Planning pregnancy</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>0.59 (0.27 - 1.28)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Personal choice</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>2.70 (0.78 - 9.38)<BR/>[Luukkainen 1986]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-04" MODIFIED="2009-11-09 17:40:27 +0100" MODIFIED_BY="[Empty name]" NO="4">
<TITLE>LNG-20 IUS versus IUD&lt;=250mm2: Life table differences with 95%CI</TITLE>
<TABLE COLS="4" ROWS="5">
<TR>
<TH>
<P>Outcomes</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>Two years</P>
</TH>
<TH>
<P>Three years</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>-0.90 (-2.01 to 0.21)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>-0.90 (-2.01 to -0.21)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>-0.56 (-1.30 to 0.18)<BR/>[Baveja 1989]</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>1.65 (-0.51 to 3.81)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>1.81 (-0.80 to 4.41)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>2.2 (-0.75 to 5.14)<BR/>[Baveja 1989]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>All Menstrual</P>
</TD>
<TD>
<P>7.95 (5.14 to 10.76)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>12.55 (9.05 to 16.05)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>12.9 (8.77 to 17.03)<BR/>[Baveja 1989]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual - Absence of menstrual bleeding</P>
</TD>
<TD>
<P>5.07 (3.36 to 6.77)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>9.80 (10.80 to 16.41)<BR/>[Baveja 1989]</P>
</TD>
<TD>
<P>13.60 (10.80 to 16.41)<BR/>[Baveja 1989]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-05" MODIFIED="2009-09-21 17:17:42 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE>LNG-20 IUS versus subdermal implants: Rate ratios with 95% CI</TITLE>
<TABLE COLS="4" ROWS="9">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>One year</P>
</TH>
<TH>
<P>Two years</P>
</TH>
<TH>
<P>Three years</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>3.01 (0.13 - 75.56)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>3.06 (0.12 - 75.56)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>3.00 (0.12 - 73.53)<BR/>[Wang 1992]</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuation</P>
</TD>
<TD>
<P>0.97 (0.72 - 1.31)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>7.18 (0.37 - 139.04)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Ovarian cysts</P>
</TD>
<TD>
<P>4.10 (0.65 - 26.04)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Breast cancer</P>
</TD>
<TD>
<P>None<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>None<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>None<BR/>[Wang 1992]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Menstrual</P>
</TD>
<TD>
<P>1.03 (.023 - 4.51)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Device problem</P>
</TD>
<TD>
<P>9.23 (0.5 - 171.51)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Adverse events</P>
</TD>
<TD>
<P>1.03 (0.11 - 9.86)<BR/>[Wang 1992]</P>
</TD>
<TD>
<P>Not available</P>
</TD>
<TD>
<P>Not available</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-06" MODIFIED="2009-09-28 17:11:32 +0200" MODIFIED_BY="[Empty name]" NO="6">
<TITLE MODIFIED="2009-09-16 19:14:30 +0200" MODIFIED_BY="[Empty name]">LNG-20 IUS versus oral contraceptives: Rate ratios with 95% CI</TITLE>
<TABLE COLS="2" ROWS="4">
<TR>
<TD>
<P>
<B>Outcome</B>
</P>
</TD>
<TD>
<P>
<B>One year</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:</P>
<P>Hormonal</P>
</TD>
<TD>
<P>1.00 (0.32 - 3.07)</P>
<P>[Suhonen 2004]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:</P>
<P>Planning pregnancy</P>
</TD>
<TD>
<P>0.21 (0.01 - 4.39)</P>
<P>[Suhonen 2004]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:</P>
<P>Patient choice</P>
</TD>
<TD>
<P>1.40 (0.48 - 4.02)</P>
<P>[Suhonen 2004]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-07" MODIFIED="2009-09-21 17:08:01 +0200" MODIFIED_BY="[Empty name]" NO="7">
<TITLE>Progestasert versus IUD &lt;=250mm2: Rate ratios with 95% CI</TITLE>
<TABLE COLS="2" ROWS="5">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>One year</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>1.41 (0.57 - 3.51)<BR/>[Larsen 1981; Fylling 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Continuation</P>
</TD>
<TD>
<P>0.97 (0.78 - 1.23)<BR/>[Larsen 1981]</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>0.11 (0.03 - 0.43)<BR/>[Fylling 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Ectopic pregnancy</P>
</TD>
<TD>
<P>3.57 (0.39 - 32.36)<BR/>[Larsen 1981;Fylling 1979]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-08" MODIFIED="2009-09-16 19:37:54 +0200" MODIFIED_BY="[Empty name]" NO="8">
<TITLE>Progestasert versus non-medicated IUD: Rate ratios with 95% CI</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Outcome</P>
</TH>
<TH>
<P>One year</P>
</TH>
</TR>
<TR>
<TD>
<P>Pregnancy</P>
</TD>
<TD>
<P>0.09 (0.03 - 0.28)<BR/>[Newton 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Expulsion</P>
</TD>
<TD>
<P>0.95 (0.54 - 1.66)<BR/>[Newton 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Ectopic pregnancy</P>
</TD>
<TD>
<P>0.29 - 7.13)<BR/>[Newton 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Planning pregnancy</P>
</TD>
<TD>
<P>1.29 (0.88 - 1.90)<BR/>[Newton 1979]</P>
</TD>
</TR>
<TR>
<TD>
<P>Discontinuation:<BR/>Personal reasons</P>
</TD>
<TD>
<P>0.46 (0.20 - 1.07)<BR/>[Newton 1979]</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-01-03 17:00:43 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2009-11-09 17:45:38 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>LNG-20 IUS vs. IUDs &gt;250mm2</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Pregnancy due to method failure</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.01.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="1" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 0.0 (0.4) vs. 0.8 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="2" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>2/7680 women months vs. 2/7740 women months<BR/>Single decrement life table probabilities (SE) = 0.3 (0.2) vs. 0.3 (0.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.01.02" NO="2" STUDIES="2">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="3" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 0.0 (0.5) vs. 1.0 (0.5)<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="4" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>2/19644 women months vs. 7/20436 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.01.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="5" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>0/10589 women months vs. 4/10869 women months<BR/>Single decrement life table probabilities (SE) = 0.0 (0.5) vs. 1.0 (0.5)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.01.04" NO="4" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="6" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>6/34944 women months vs. 10/38268 women months<BR/>Single decrement life table probabilities (SE) = 1.1 (0.5) vs. 1.4 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Continuation of method</NAME>
<TR>
<TH>
<P>Continuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.02.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="7" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>339/4809 women months vs. 350/4599 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="8" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>743/11892 women months vs. 791/12084 women months<BR/>Life table probabilities (SE) = 73.5 (1.4) vs. 79.8 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.02.02" NO="2" STUDIES="2">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="9" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>257/8321 women months vs. 276/8333</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="10" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>548/19644 women months vs. 605/20436 women months<BR/>Life table probabilities (SE) = 59.4 (1.6) vs. 67.5 (1.5)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.02.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="11" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>150/10589 women months vs. 170/10869 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.02.04" NO="4" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="12" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>298/34944 women months vs. 335/38268 women months<BR/>Life table probabilities (SE) = 33 (1.5) vs. 40.6 (1.6)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.4826803727804134" CI_START="0.4502089003811151" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.252171594075014" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.541913618383768" LOG_CI_START="-0.3465859234887716" LOG_EFFECT_SIZE="0.09766384744749813" METHOD="PETO" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6665568024010511" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="49" TOTAL_2="37" WEIGHT="100.0" Z="0.43087838443966353">
<NAME>Planned pregnancy after discontinuation of method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.4826803727804134" CI_START="0.4502089003811151" DF="0" EFFECT_SIZE="1.252171594075014" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="0.541913618383768" LOG_CI_START="-0.3465859234887716" LOG_EFFECT_SIZE="0.09766384744749813" NO="1" P_CHI2="1.0" P_Z="0.6665568024010511" STUDIES="1" TAU2="0.0" TOTAL_1="49" TOTAL_2="37" WEIGHT="100.0" Z="0.43087838443966353">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="3.4826803727804134" CI_START="0.4502089003811151" EFFECT_SIZE="1.252171594075014" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="28" LOG_CI_END="0.541913618383768" LOG_CI_START="-0.3465859234887716" LOG_EFFECT_SIZE="0.09766384744749813" ORDER="655" O_E="0.8255813953488342" SE="0.5219090290395944" STUDY_ID="STD-Sivin-1994" TOTAL_1="49" TOTAL_2="37" VAR="3.671219737218846" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.531117614920593" CI_END="7.683344728034569" CI_START="3.642594272935512" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="5.290303157979509" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="32" I2="93.95080221861453" I2_Q="93.95080221861453" ID="CMP-001.04" LOG_CI_END="0.8855503190822127" LOG_CI_START="0.5614108004381497" LOG_EFFECT_SIZE="0.7234805597601811" METHOD="PETO" NO="4" P_CHI2="4.785876232471509E-5" P_Q="4.785876232471509E-5" P_Z="2.1469320838701494E-18" Q="16.531117614920593" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="365" WEIGHT="100.0" Z="8.749293184469323">
<NAME>Amenorrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.03808234312129" CI_START="1.3706698651582068" DF="0" EFFECT_SIZE="2.3526320963431138" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="20" I2="0.0" ID="CMP-001.04.01" LOG_CI_END="0.6061751706746293" LOG_CI_START="0.13693286470549867" LOG_EFFECT_SIZE="0.371554017690064" NO="1" P_CHI2="1.0" P_Z="0.0019101016855377518" STUDIES="1" TAU2="0.0" TOTAL_1="215" TOTAL_2="226" WEIGHT="47.71661693360558" Z="3.103865460211044">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="4.03808234312129" CI_START="1.3706698651582068" EFFECT_SIZE="2.3526320963431138" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="20" LOG_CI_END="0.6061751706746293" LOG_CI_START="0.13693286470549867" LOG_EFFECT_SIZE="0.371554017690064" ORDER="656" O_E="11.26077097505669" SE="0.27563525331314337" STUDY_ID="STD-Sivin-1994" TOTAL_1="215" TOTAL_2="226" VAR="13.162260300258358" WEIGHT="47.71661693360558"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="18.569832295028945" CI_START="6.614959318755753" DF="0" EFFECT_SIZE="11.083261486933043" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="12" I2="0.0" ID="CMP-001.04.02" LOG_CI_END="1.2688079816249502" LOG_CI_START="0.820527177670274" LOG_EFFECT_SIZE="1.0446675796476121" NO="2" P_CHI2="1.0" P_Z="6.543844562012011E-20" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="139" WEIGHT="52.28338306639443" Z="9.134947621504507">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="18.569832295028945" CI_START="6.614959318755753" EFFECT_SIZE="11.083261486933043" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="12" LOG_CI_END="1.2688079816249502" LOG_CI_START="0.820527177670274" LOG_EFFECT_SIZE="1.0446675796476121" ORDER="657" O_E="34.69111969111969" SE="0.2633223632687443" STUDY_ID="STD-Sivin-1994" TOTAL_1="120" TOTAL_2="139" VAR="14.42196747216052" WEIGHT="52.28338306639443"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.8699554582004154" CI_END="1.2556040646785664" CI_START="0.511676671715201" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.8015380894298205" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="53" I2="65.15625365743333" I2_Q="65.15625365743333" ID="CMP-001.05" LOG_CI_END="0.09885271294120554" LOG_CI_START="-0.2910043828643305" LOG_EFFECT_SIZE="-0.09607583496156245" METHOD="PETO" NO="5" P_CHI2="0.09024749243319163" P_Q="0.09024749243319163" P_Z="0.33403341425422073" Q="2.8699554582004154" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="335" TOTAL_2="365" WEIGHT="100.0" Z="0.9660215414070842">
<NAME>Prolonged bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3911120419552419" CI_START="0.5534133152251978" DF="0" EFFECT_SIZE="0.8774166211031934" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.1433621100375627" LOG_CI_START="-0.2569503958649957" LOG_EFFECT_SIZE="-0.056794142913716476" NO="1" P_CHI2="1.0" P_Z="0.5781166024254849" STUDIES="1" TAU2="0.0" TOTAL_1="215" TOTAL_2="226" WEIGHT="94.8445916044621" Z="0.5561378822913943">
<NAME>At 3 months</NAME>
<DICH_DATA CI_END="1.3911120419552419" CI_START="0.5534133152251978" EFFECT_SIZE="0.8774166211031934" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="49" LOG_CI_END="0.1433621100375627" LOG_CI_START="-0.2569503958649957" LOG_EFFECT_SIZE="-0.056794142913716476" ORDER="658" O_E="-2.3650793650793673" SE="0.2351455475460255" STUDY_ID="STD-Sivin-1994" TOTAL_1="215" TOTAL_2="226" VAR="18.08533177580797" WEIGHT="94.8445916044621"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0958771565884635" CI_START="0.02102556129609396" DF="0" EFFECT_SIZE="0.1517940457621441" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.039761874216024805" LOG_CI_START="-1.6772524014971135" LOG_EFFECT_SIZE="-0.8187452636405445" NO="2" P_CHI2="1.0" P_Z="0.061596664940243316" STUDIES="1" TAU2="0.0" TOTAL_1="120" TOTAL_2="139" WEIGHT="5.155408395537897" Z="1.8691879874810287">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="1.0958771565884635" CI_START="0.02102556129609396" EFFECT_SIZE="0.1517940457621441" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.039761874216024805" LOG_CI_START="-1.6772524014971135" LOG_EFFECT_SIZE="-0.8187452636405445" ORDER="659" O_E="-1.8532818532818534" SE="1.0085826849116382" STUDY_ID="STD-Sivin-1994" TOTAL_1="120" TOTAL_2="139" VAR="0.9830531155843178" WEIGHT="5.155408395537897"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.06" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Expulsion</NAME>
<TR>
<TH>
<P>Expulsion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.06.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="18" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 6.5 (1.2) vs. 5.3 (1.1)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="19" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>43/7680 women months vs. 39/7740 women months<BR/>Single decrement life table probabilities (SE) = 6.4 (1.0) vs. 5.8 (1.9)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.06.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="20" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 9.2 (1.4) vs. 7.1 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.06.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="21" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 10.6 (1.6) vs. 7.6 (1.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.06.04" NO="4" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="22" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>99/34944 women months vs. 71/38268 women months<BR/>Single decrement life table probabilities (SE) = 11.8 (1.2) vs. 7.4 (0.9)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.07" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Embedded</NAME>
<TR>
<TH>
<P>Embedded</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.07.01" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="23" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>3/34944 women months vs. 0/38268 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.08" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Ectopic pregnancy</NAME>
<TR>
<TH>
<P>Ectopic pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.08.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="24" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>0/7680 women months vs. 0/7740 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.08.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="25" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>0/19644 women months vs. 0/20436 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.08.03" NO="3" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="26" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>0/34944 women months vs. 2/38268 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.09" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pelvic inflammatory disease</NAME>
<TR>
<TH>
<P>PID</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.09.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="27" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>10/7680 women months vs. 8/7740 women months<BR/>Single decrement life table probabilities (SE) = 1.6 (0.5) vs. 1.3 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.10" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Hormonal reasons for discontinuation</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.10.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="28" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>4/7680 women months vs. 5/7740 women months<BR/>Single decrement life table probabilities (SE) = 0.7 (0.4) vs. 0.8 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.10.02" NO="2" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="29" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>10/10589 women months vs. 6/10869 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.10.03" NO="3" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="30" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>31/34994 women months vs. 8/38268 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.11" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: all</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.11.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="31" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 13.8 (1.7) vs. 7.1 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="32" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>69/7680 women months vs. 47/7740 women months<BR/>Single decremt life table probabilities (SE) = 11.1 (7.5) vs. 1.6 (1.1)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.11.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="33" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 21.9 (2.1) vs. 10.8 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.11.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="34" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 27.9 (2.3) vs. 13.4 (1.8)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.11.04" NO="4" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="35" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>252/34944 women months vs. 186/38268 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: bleeding &amp; pain</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.12.01" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="36" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>118/34944 women months vs. 183/38268 women months<BR/>Single decrement life table probabilities (SE) = 15.4 (1.4) vs. 23.3 (0.6)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.13" NO="13" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: pain</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.13.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="37" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 2.5 (0.6) vs. 3.4 (0.8)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.13.02" NO="2" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="38" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>15/7680 women months vs. 47/7740 women months<BR/>Single decrement life table probabilities (SE) = 19.7 (1.6) vs. 0.4 (0.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.14" MODIFIED="2009-11-09 17:45:38 +0100" MODIFIED_BY="[Empty name]" NO="14" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: absence of menstrual bleeding</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.14.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="39" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>32/7680 women months vs. 0/7740 women months<BR/>Single decrement life table probabilities (SE) = 5.6 (1.0) vs. 0.0</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.14.02" NO="2" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="40" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>134/34944 women months vs. 3/38268 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.15" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation due to adverse event</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.15.01" NO="1" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="41" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>2/10589 women months vs. 2/10869 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.16" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation because planning pregnancy</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.16.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="42" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>15/7680 women months vs. 16/7740 women months<BR/>Single decrement life table probabilities (SE) = 2.8 (0.7) vs. 2.9 (0.7)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.16.02" NO="2" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="43" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>155/34944 women months vs. 153/38268 women months<BR/>Single decrement life table probabilities (SE) = 25.0 (1.9) vs. 23.5 (1.7)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-001.17" NO="17" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Personal reasons for discontinuation</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-001.17.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="44" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>18/7680 women months vs. 13/7740 women months<BR/>Single decrement life table probabilities (SE) = 3.0 (0.7) vs. 2.2 (0.6)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-001.17.02" NO="2" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="45" STUDY_ID="STD-Sivin-1994">
<TR>
<TD>
<P>56/34944 women months vs. 55/38268 women months<BR/>Single decrement life table probabilities (SE) = 9.5 (1.3) vs. 9.4 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-11-09 17:46:22 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>LNG-20 IUS vs. IUD&lt;=250mm2</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Pregnancy due to method failure</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.01.01" NO="1" STUDIES="3">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="46" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>1/18664 women months vs. 8/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="47" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 0.0 vs. CuT 220C 0.0 and vs. CuT 200B 0.9 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="48" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>1/1654 women months vs. 4/1708 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.01.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="49" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 0.0 vs. CuT 220C 0.0 and vs. CuT 200B 0.9 (0.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.01.03" NO="3" STUDIES="2">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="50" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>3/46200 women months vs. 24/23568 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="51" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>0/10589 women months vs. 7/24225 women months (vs. CuT 220C 1/12076 women months and vs. CuT 220B 6/12149 women months)<BR/>Single decrement life table probabilities (SE) = 0.0 vs. CuT 220C 0.3 (0.3) and vs. CuT 200B 1.6 (0.6)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.01.04" NO="4" STUDIES="2">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="52" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>5/67380 women months vs. 35/33312 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="53" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>1/5495 women months vs. 7/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Continuation of method</NAME>
<TR>
<TH>
<P>Continuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.02.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="54" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>1362/18664 women months vs. 680/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="55" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>339/4809 women months vs. 791/9814 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.02.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="56" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>257/8321 women months vs. 617/18819 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.02.03" NO="3" STUDIES="2">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="57" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>902/46200 women months vs. 435/23568 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="58" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>150/10589 women months vs. 344/24255 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.02.04" NO="4" STUDIES="2">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="59" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>67/5495 women months vs. 53/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="60" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>736/67380 women months vs. 315/33312 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="200" EVENTS_2="96" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="PETO" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="276" TOTAL_2="142" WEIGHT="0.0" Z="0.0">
<NAME>Planned pregnancy after discontinuation of method</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="96" EVENTS_2="46" I2="0.0" ID="CMP-002.03.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="2.293648313414642" CI_START="0.6745948051665254" EFFECT_SIZE="1.2438984030492521" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="46" LOG_CI_END="0.3605268280149865" LOG_CI_START="-0.1709570074933918" LOG_EFFECT_SIZE="0.09478491026079731" ORDER="703" O_E="2.2392344497607723" SE="0.31219623586503753" STUDY_ID="STD-Andersson-1994" TOTAL_1="138" TOTAL_2="71" VAR="10.259936550480493" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="104" EVENTS_2="50" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="138" TOTAL_2="71" WEIGHT="0.0" Z="0.0">
<NAME>At 2 years</NAME>
<DICH_DATA CI_END="2.4646288174275868" CI_START="0.6736964549472504" EFFECT_SIZE="1.2885696322130982" ESTIMABLE="YES" EVENTS_1="104" EVENTS_2="50" LOG_CI_END="0.39175152211984937" LOG_CI_START="-0.17153573793884305" LOG_EFFECT_SIZE="0.11010789209050315" ORDER="704" O_E="2.3157894736842053" SE="0.3308777248753826" STUDY_ID="STD-Andersson-1994" TOTAL_1="138" TOTAL_2="71" VAR="9.134082676326443" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.921254921850879" CI_START="0.5323022208248354" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.6185162724379307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.6920758621455776" LOG_CI_START="-0.27384172189795847" LOG_EFFECT_SIZE="0.20911707012380945" METHOD="PETO" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.3960772979349857" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.00000000000001" Z="0.848647819991918">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.921254921850879" CI_START="0.5323022208248354" DF="0" EFFECT_SIZE="1.6185162724379307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" I2="0.0" ID="CMP-002.04.01" LOG_CI_END="0.6920758621455776" LOG_CI_START="-0.27384172189795847" LOG_EFFECT_SIZE="0.20911707012380945" NO="1" P_CHI2="1.0" P_Z="0.3960772979349857" STUDIES="1" TAU2="0.0" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.00000000000001" Z="0.848647819991918">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="4.921254921850879" CI_START="0.5323022208248354" EFFECT_SIZE="1.6185162724379307" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.6920758621455776" LOG_CI_START="-0.27384172189795847" LOG_EFFECT_SIZE="0.20911707012380945" ORDER="705" O_E="1.495718363463368" SE="0.567384770236327" STUDY_ID="STD-Andersson-1994" TOTAL_1="736" TOTAL_2="315" VAR="3.1063089749149246" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.071237688346919" CI_START="0.34663975937960706" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.450700648454042" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.7832772357912152" LOG_CI_START="-0.46012162543959767" LOG_EFFECT_SIZE="0.16157780517580878" METHOD="PETO" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.6104797814663907" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="0.5093887226696246">
<NAME>Breast tenderness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.071237688346919" CI_START="0.34663975937960706" DF="0" EFFECT_SIZE="1.450700648454042" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-002.05.01" LOG_CI_END="0.7832772357912152" LOG_CI_START="-0.46012162543959767" LOG_EFFECT_SIZE="0.16157780517580878" NO="1" P_CHI2="1.0" P_Z="0.6104797814663907" STUDIES="1" TAU2="0.0" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="0.5093887226696246">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="6.071237688346919" CI_START="0.34663975937960706" EFFECT_SIZE="1.450700648454042" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.7832772357912152" LOG_CI_START="-0.46012162543959767" LOG_EFFECT_SIZE="0.16157780517580878" ORDER="706" O_E="0.6974310180780208" SE="0.730378646010608" STUDY_ID="STD-Andersson-1994" TOTAL_1="736" TOTAL_2="315" VAR="1.8745795088000106" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="9.505141899572141" CI_START="0.9519652759075706" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="3.0080832819200336" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.9779586047092118" LOG_CI_START="-0.021378892746583736" LOG_EFFECT_SIZE="0.478289855981314" METHOD="PETO" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.060640903363414926" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="1.8761047079306479">
<NAME>Acne</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="9.505141899572141" CI_START="0.9519652759075706" DF="0" EFFECT_SIZE="3.0080832819200336" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" I2="0.0" ID="CMP-002.06.01" LOG_CI_END="0.9779586047092118" LOG_CI_START="-0.021378892746583736" LOG_EFFECT_SIZE="0.478289855981314" NO="1" P_CHI2="1.0" P_Z="0.060640903363414926" STUDIES="1" TAU2="0.0" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="1.8761047079306479">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="9.505141899572141" CI_START="0.9519652759075706" EFFECT_SIZE="3.0080832819200336" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="1" LOG_CI_END="0.9779586047092118" LOG_CI_START="-0.021378892746583736" LOG_EFFECT_SIZE="0.478289855981314" ORDER="707" O_E="3.196003805899144" SE="0.5870157928059276" STUDY_ID="STD-Andersson-1994" TOTAL_1="736" TOTAL_2="315" VAR="2.9020201864745734" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="86.13407882042186" CI_START="0.20246174878907658" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.175985659496303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="1.9351750134214314" LOG_CI_START="-0.6936570161975394" LOG_EFFECT_SIZE="0.620758998611946" METHOD="PETO" NO="7" P_CHI2="1.0" P_Q="1.0" P_Z="0.35463736494967235" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="0.9256318141672292">
<NAME>Nausea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="86.13407882042186" CI_START="0.20246174878907658" DF="0" EFFECT_SIZE="4.175985659496303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-002.07.01" LOG_CI_END="1.9351750134214314" LOG_CI_START="-0.6936570161975394" LOG_EFFECT_SIZE="0.620758998611946" NO="1" P_CHI2="1.0" P_Z="0.35463736494967235" STUDIES="1" TAU2="0.0" TOTAL_1="736" TOTAL_2="315" WEIGHT="100.0" Z="0.9256318141672292">
<NAME>At 5 years</NAME>
<DICH_DATA CI_END="86.13407882042186" CI_START="0.20246174878907658" EFFECT_SIZE="4.175985659496303" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.9351750134214314" LOG_CI_START="-0.6936570161975394" LOG_EFFECT_SIZE="0.620758998611946" ORDER="708" O_E="0.599429115128449" SE="1.5441889471266" STUDY_ID="STD-Andersson-1994" TOTAL_1="736" TOTAL_2="315" VAR="0.4193717007317575" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.08" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Ovarian cysts</NAME>
<TR>
<TH>
<P>Ovarian cysts</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.08.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="67" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>12/18664 women months vs. 4/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.09" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Expulsion</NAME>
<TR>
<TH>
<P>Expulsion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.09.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="68" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>62/18664 women months vs. 32/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="69" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 6.5 (1.2) vs. CuT 220C 4.8 (1.0) and vs. CuT 200B 4.9 (1.0)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.09.02" NO="2" STUDIES="2">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="70" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 9.2 (1.4) vs. CuT 220C 7.1 (1.2) and vs. CuT 200B 7.7 (1.3)</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="71" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>1/3083 women months vs. 9/2989 women montths</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.09.04" NO="4" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="72" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>2/5495 women months vs. 7/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.10" NO="10" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Ectopic pregnancy</NAME>
<TR>
<TH>
<P>Ectopic pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.10.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="73" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>0/18664 women months vs. 1/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="74" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>1/1654 women months vs. 0/1708 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.10.02" NO="2" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="75" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>1/46200 women months vs. 5/23568 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.10.03" NO="3" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="76" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>1/67380 women months vs. 7/33312 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.11" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pelvic inflammatory disease</NAME>
<TR>
<TH>
<P>PID</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.11.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="77" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>0/1654 women months vs. 0/1708 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.11.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="78" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>0/3083 women months vs. 3/2989 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.12" NO="12" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Hormonal reasons for discontinuation</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.12.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="79" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>54/18664 women months vs. 5/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.12.02" NO="2" STUDIES="2">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="80" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>110/46200 women months vs. 5/23568 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="81" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Total: 10/10589 women months vs. 27/24225 women months (vs. CuT220C 13/12076 women months and vs. CuT200B 14/12149 women months)<BR/>
</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.12.03" NO="3" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="82" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>11/5495 women months vs. 2/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.13" NO="13" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: all</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.13.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="83" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>153/18664 women months vs. 65/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="84" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 13.8 (1.7) vs. CuT 220C 6.0 (1.1) and vs. CuT 200B 5.7 (1.1)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.13.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="85" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 21.9 (2.1) vs. CuT 220C 9.9 (1.4) and vs. CuT 200B 8.8 (1.4)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.13.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="86" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Single decrement life table probabilities (SE) = 27.9 (2.3) vs. CuT 220C 15.4 (1.9) and vs. CuT 200B 14.6 (1.9)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.13.04" NO="4" STUDIES="1">
<NAME>At 5 year</NAME>
<OTHER_DATA ORDER="87" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>26/5495 women months vs. 21/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.14" NO="14" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: bleeding &amp; pain</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.14.01" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="88" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>11/5495 women months vs. 21/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.15" MODIFIED="2009-11-09 17:46:22 +0100" MODIFIED_BY="[Empty name]" NO="15" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: absence of menstrual bleeding</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.15.01" MODIFIED="2009-11-09 17:46:22 +0100" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA MODIFIED="2009-11-09 17:46:22 +0100" MODIFIED_BY="[Empty name]" ORDER="89" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>15/5495 women months vs. 0/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.16" NO="16" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES">
<NAME>Discontinuation due to adverse event</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.16.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="90" STUDY_ID="STD-Andersson-1994">
<TR>
<TD>
<P>42/18664 women months vs. 21/9326 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.16.02" NO="2" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="91" STUDY_ID="STD-Baveja-1989">
<TR>
<TD>
<P>Total: 2/10589 women months vs. 4/24225 women months (vs. CuT220C 0/12076 women months and vs. CuT200B 4/12149 women months)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-002.16.03" NO="3" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="92" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>5/5495 women months vs. 6/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.17" NO="17" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation because planning pregnancy</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.17.01" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="93" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>10/5495 women months vs. 16/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-002.18" NO="18" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation for personal reasons</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-002.18.01" NO="1" STUDIES="1">
<NAME>At 5 years</NAME>
<OTHER_DATA ORDER="94" STUDY_ID="STD-Luukkainen-1986">
<TR>
<TD>
<P>6/5495 women months vs. 3/5176 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-11-09 17:48:04 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>LNG-20 IUS vs. Norplant-2</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pregnancy</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.01.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="95" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>1/1157 women months vs. 0/1187 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.01.02" NO="2" STUDIES="1">
<NAME>At 2 years</NAME>
<OTHER_DATA ORDER="96" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>1/2171 women months vs. 0/2218 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-003.01.03" NO="3" STUDIES="1">
<NAME>At 3 years</NAME>
<OTHER_DATA ORDER="97" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>1/3098 women months vs. 0/3093 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Continuation of method</NAME>
<TR>
<TH>
<P>Continuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.02.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="98" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>81/1157 women months vs. 93/1187 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Expulsion</NAME>
<TR>
<TH>
<P>Expulsion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.03.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="99" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>3/1157 women months vs. 0/1187 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Breast cancer</NAME>
<TR>
<TH>
<P>Breast cancer</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.04.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="100" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>0/1157 women months vs. 0/1187 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-003.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Ovarian cysts</NAME>
<TR>
<TH>
<P>Ovarian cysts</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-003.05.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="101" STUDY_ID="STD-Wang-1992">
<TR>
<TD>
<P>4/1157 women months vs. 1/1187 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.4232389450634999" CI_END="0.3543351928265528" CI_START="0.14327279056748793" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.22531442890442938" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.45058571108387646" LOG_CI_START="-0.8438362801429173" LOG_EFFECT_SIZE="-0.6472109956133969" METHOD="PETO" NO="6" P_CHI2="0.8092726935137823" P_Q="0.8092726935137823" P_Z="1.108145685024E-10" Q="0.4232389450634999" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="244" WEIGHT="300.0" Z="6.451409567369859">
<NAME>Spotting</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5109810514146267" CI_START="0.13650532440862412" DF="0" EFFECT_SIZE="0.2641053467652888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="36" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="-0.291595204402758" LOG_CI_START="-0.8648504085778971" LOG_EFFECT_SIZE="-0.5782228064903275" NO="1" P_CHI2="1.0" P_Z="7.68886764784188E-5" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="99.99999999999999" Z="3.953896510687321">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="0.5109810514146268" CI_START="0.13650532440862406" EFFECT_SIZE="0.2641053467652888" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="36" LOG_CI_END="-0.2915952044027579" LOG_CI_START="-0.8648504085778972" LOG_EFFECT_SIZE="-0.5782228064903275" ORDER="744" O_E="-11.741935483870968" SE="0.3367329445915026" STUDY_ID="STD-Wang-1992" TOTAL_1="90" TOTAL_2="96" VAR="8.819191720336361" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4455493123472905" CI_START="0.08330398053621327" DF="0" EFFECT_SIZE="0.19265521338313663" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="-0.3511042222777605" LOG_CI_START="-1.079334246088894" LOG_EFFECT_SIZE="-0.7152192341833272" NO="2" P_CHI2="1.0" P_Z="1.181692980708215E-4" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="3.8498932870507363">
<NAME>At 2 years</NAME>
<DICH_DATA CI_END="0.4455493123472905" CI_START="0.08330398053621327" EFFECT_SIZE="0.19265521338313663" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="22" LOG_CI_END="-0.3511042222777605" LOG_CI_START="-1.079334246088894" LOG_EFFECT_SIZE="-0.7152192341833272" ORDER="745" O_E="-9.0" SE="0.4277659207834151" STUDY_ID="STD-Wang-1992" TOTAL_1="79" TOTAL_2="79" VAR="5.464968152866243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5045159149390779" CI_START="0.07878650523495256" DF="0" EFFECT_SIZE="0.19937162730304564" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="-0.2971251294048617" LOG_CI_START="-1.1035481632703996" LOG_EFFECT_SIZE="-0.7003366463376307" NO="3" P_CHI2="1.0" P_Z="6.634491824039771E-4" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="3.4042544576031863">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="0.5045159149390779" CI_START="0.07878650523495254" EFFECT_SIZE="0.19937162730304564" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="18" LOG_CI_END="-0.2971251294048617" LOG_CI_START="-1.1035481632703998" LOG_EFFECT_SIZE="-0.7003366463376307" ORDER="746" O_E="-7.186567164179104" SE="0.47369688195101456" STUDY_ID="STD-Wang-1992" TOTAL_1="65" TOTAL_2="69" VAR="4.456551687751346" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="12.160868116134017" CI_END="4.252024931205779" CI_START="1.7969985937701254" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.764214684508477" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="35" I2="83.55380569133409" I2_Q="83.55380569133409" ID="CMP-003.07" LOG_CI_END="0.6285958022890188" LOG_CI_START="0.25454773725470903" LOG_EFFECT_SIZE="0.44157176977186396" METHOD="PETO" MODIFIED="2009-11-09 17:47:19 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0022871912751878387" P_Q="0.0022871912751878387" P_Z="3.700006480844301E-6" Q="12.160868116134017" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="244" WEIGHT="300.0" Z="4.627559109351792">
<NAME>Infrequent menstrual bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.3721788573505487" CI_START="0.9321840352248812" DF="0" EFFECT_SIZE="1.7729893667884937" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="0.5279106011544846" LOG_CI_START="-0.03049833915617948" LOG_EFFECT_SIZE="0.24870613099915256" NO="1" P_CHI2="1.0" P_Z="0.08083332529023166" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="100.0" Z="1.7458712577970188">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="3.3721788573505487" CI_START="0.9321840352248812" EFFECT_SIZE="1.7729893667884937" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.5279106011544846" LOG_CI_START="-0.03049833915617948" LOG_EFFECT_SIZE="0.24870613099915256" ORDER="747" O_E="5.322580645161292" SE="0.3280121757073186" STUDY_ID="STD-Wang-1992" TOTAL_1="90" TOTAL_2="96" VAR="9.294372416120595" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.395536164804138" CI_START="3.5608091047352124" DF="0" EFFECT_SIZE="7.1595919047931496" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="1.1582278449056211" LOG_CI_START="0.5515486917359373" LOG_EFFECT_SIZE="0.8548882683207792" NO="2" P_CHI2="1.0" P_Z="3.3197519058841684E-8" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="5.5236782340727695">
<NAME>At 2 years</NAME>
<DICH_DATA CI_END="14.395536164804138" CI_START="3.5608091047352124" EFFECT_SIZE="7.1595919047931496" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="6" LOG_CI_END="1.1582278449056211" LOG_CI_START="0.5515486917359373" LOG_EFFECT_SIZE="0.8548882683207792" ORDER="748" O_E="15.5" SE="0.3563663376821141" STUDY_ID="STD-Wang-1992" TOTAL_1="79" TOTAL_2="79" VAR="7.87420382165605" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.0289640962907347" CI_START="0.37775126839331785" DF="0" EFFECT_SIZE="1.069670523708887" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="0.4812941254704498" LOG_CI_START="-0.422794068735346" LOG_EFFECT_SIZE="0.02925002836755187" NO="3" P_CHI2="1.0" P_Z="0.8990815180858928" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="0.12682170282632177">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="3.0289640962907347" CI_START="0.37775126839331785" EFFECT_SIZE="1.069670523708887" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.4812941254704498" LOG_CI_START="-0.422794068735346" LOG_EFFECT_SIZE="0.02925002836755187" ORDER="749" O_E="0.23880597014925353" SE="0.5310658805852226" STUDY_ID="STD-Wang-1992" TOTAL_1="65" TOTAL_2="69" VAR="3.5457098973765446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.275841939314889" CI_END="7.606386318512561" CI_START="2.416251220659489" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="4.287066622635297" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="10" I2="62.0913586304347" I2_Q="62.0913586304347" ID="CMP-003.08" LOG_CI_END="0.8811783788901346" LOG_CI_START="0.3831420864367321" LOG_EFFECT_SIZE="0.6321602326634335" METHOD="PETO" MODIFIED="2009-11-09 17:48:04 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.07150992230497522" P_Q="0.07150992230497522" P_Z="6.505042878536701E-7" Q="5.275841939314889" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="244" WEIGHT="300.0" Z="4.975586346831201">
<NAME>Absence of menstrual bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="5.715772748120973" CI_START="1.063508991766355" DF="0" EFFECT_SIZE="2.4655173316202306" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" I2="0.0" ID="CMP-003.08.01" LOG_CI_END="0.7570749534641011" LOG_CI_START="0.02674116613155656" LOG_EFFECT_SIZE="0.39190805979782883" NO="1" P_CHI2="1.0" P_Z="0.03542277360251421" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="100.0" Z="2.10349211765267">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="5.715772748120973" CI_START="1.063508991766355" EFFECT_SIZE="2.4655173316202306" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.7570749534641011" LOG_CI_START="0.02674116613155656" LOG_EFFECT_SIZE="0.39190805979782883" ORDER="750" O_E="4.903225806451612" SE="0.42900168188968935" STUDY_ID="STD-Wang-1992" TOTAL_1="90" TOTAL_2="96" VAR="5.433529262873695" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="24.72168653235733" CI_START="3.960066231125377" DF="0" EFFECT_SIZE="9.894418427237413" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" I2="0.0" ID="CMP-003.08.02" LOG_CI_END="1.3930780953290585" LOG_CI_START="0.5977024494537311" LOG_EFFECT_SIZE="0.9953902723913948" NO="2" P_CHI2="1.0" P_Z="9.310434868686303E-7" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="79" WEIGHT="100.0" Z="4.90567971138118">
<NAME>At 2 years</NAME>
<DICH_DATA CI_END="24.72168653235733" CI_START="3.960066231125376" EFFECT_SIZE="9.894418427237413" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" LOG_CI_END="1.3930780953290585" LOG_CI_START="0.597702449453731" LOG_EFFECT_SIZE="0.9953902723913948" ORDER="751" O_E="10.5" SE="0.4672075915601124" STUDY_ID="STD-Wang-1992" TOTAL_1="79" TOTAL_2="79" VAR="4.5812101910828025" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="11.915976061023294" CI_START="0.5735858236718123" DF="0" EFFECT_SIZE="2.6143517253452417" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" I2="0.0" ID="CMP-003.08.03" LOG_CI_END="1.0761296220542573" LOG_CI_START="-0.24140159091275834" LOG_EFFECT_SIZE="0.4173640155707494" NO="3" P_CHI2="1.0" P_Z="0.2143309422026175" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="1.2417443031494426">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="11.915976061023297" CI_START="0.5735858236718121" EFFECT_SIZE="2.6143517253452417" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.0761296220542576" LOG_CI_START="-0.24140159091275853" LOG_EFFECT_SIZE="0.4173640155707494" ORDER="752" O_E="1.6044776119402986" SE="0.7739243563815129" STUDY_ID="STD-Wang-1992" TOTAL_1="65" TOTAL_2="69" VAR="1.6695636116354597" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15789232841140732" CI_END="0.2755461793813241" CI_START="0.10584109584108001" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.1707750262202941" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="71" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="-0.5598056063591121" LOG_CI_START="-0.9753456722666028" LOG_EFFECT_SIZE="-0.7675756393128575" METHOD="PETO" NO="9" P_CHI2="0.924089696136737" P_Q="0.924089696136737" P_Z="4.460559932151485E-13" Q="0.15789232841140732" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="234" TOTAL_2="244" WEIGHT="300.0" Z="7.240796890081005">
<NAME>Prolonged bleeding</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.31673189340220853" CI_START="0.0752756993506072" DF="0" EFFECT_SIZE="0.15440924448520957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="33" I2="0.0" ID="CMP-003.09.01" LOG_CI_END="-0.4993082030278565" LOG_CI_START="-1.1233452009736389" LOG_EFFECT_SIZE="-0.8113267020007476" NO="1" P_CHI2="1.0" P_Z="3.461730700235339E-7" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="96" WEIGHT="100.0" Z="5.096400120030332">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="0.31673189340220853" CI_START="0.0752756993506072" EFFECT_SIZE="0.15440924448520957" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="33" LOG_CI_END="-0.4993082030278565" LOG_CI_START="-1.1233452009736389" LOG_EFFECT_SIZE="-0.8113267020007476" ORDER="753" O_E="-13.903225806451612" SE="0.36656242162631164" STUDY_ID="STD-Wang-1992" TOTAL_1="90" TOTAL_2="96" VAR="7.442247658688866" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.4020512440713099" CI_START="0.07891580732467826" DF="0" EFFECT_SIZE="0.17812410985540023" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" I2="0.0" ID="CMP-003.09.02" LOG_CI_END="-0.39571858970392343" LOG_CI_START="-1.1028359962040002" LOG_EFFECT_SIZE="-0.7492772929539617" NO="2" P_CHI2="1.0" P_Z="3.2722406256640514E-5" STUDIES="1" TAU2="0.0" TOTAL_1="79" TOTAL_2="79" WEIGHT="99.99999999999999" Z="4.153642648657591">
<NAME>At 2 years</NAME>
<DICH_DATA CI_END="0.4020512440713099" CI_START="0.07891580732467826" EFFECT_SIZE="0.17812410985540023" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="24" LOG_CI_END="-0.39571858970392343" LOG_CI_START="-1.1028359962040002" LOG_EFFECT_SIZE="-0.7492772929539617" ORDER="754" O_E="-10.0" SE="0.4153642648657591" STUDY_ID="STD-Wang-1992" TOTAL_1="79" TOTAL_2="79" VAR="5.7961783439490455" WEIGHT="99.99999999999999"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.5576826876489303" CI_START="0.06955029373849572" DF="0" EFFECT_SIZE="0.19694414116407946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" I2="0.0" ID="CMP-003.09.03" LOG_CI_END="-0.2536128372642923" LOG_CI_START="-1.1577010314700882" LOG_EFFECT_SIZE="-0.7056569343671903" NO="3" P_CHI2="1.0" P_Z="0.00221652332442489" STUDIES="1" TAU2="0.0" TOTAL_1="65" TOTAL_2="69" WEIGHT="100.0" Z="3.0595735806850146">
<NAME>At 3 years</NAME>
<DICH_DATA CI_END="0.5576826876489303" CI_START="0.06955029373849572" EFFECT_SIZE="0.19694414116407946" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="14" LOG_CI_END="-0.2536128372642923" LOG_CI_START="-1.1577010314700882" LOG_EFFECT_SIZE="-0.7056569343671903" ORDER="755" O_E="-5.7611940298507465" SE="0.5310658805852226" STUDY_ID="STD-Wang-1992" TOTAL_1="65" TOTAL_2="69" VAR="3.5457098973765446" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2009-11-09 17:48:24 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>LNG-IUS vs. combined oral contraceptives</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-004.01" MODIFIED="2009-09-16 19:47:01 +0200" MODIFIED_BY="[Empty name]" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pregnancy</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.01.01" MODIFIED="2009-09-16 19:46:47 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA MODIFIED="2009-09-16 19:46:47 +0200" MODIFIED_BY="[Empty name]" ORDER="114" STUDY_ID="STD-Suhonen-2004">
<TR>
<TD>
<P>0/1128 women months vs. 0/1188 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.7732312900979614" CI_START="0.5629417369060513" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.9991125574147813" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="59" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.2487653861717288" LOG_CI_START="-0.2495365512402564" LOG_EFFECT_SIZE="-3.8558253426376955E-4" METHOD="PETO" MODIFIED="2009-09-16 19:12:03 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.9975798501351056" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="EFFECT_SIZE" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.00000000000001" Z="0.003033212690882618">
<NAME>Headaches</NAME>
<GROUP_LABEL_1>LNG-IUS 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral contraceptives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7732312900979614" CI_START="0.5629417369060513" DF="0" EFFECT_SIZE="0.9991125574147813" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="59" I2="0.0" ID="CMP-004.02.01" LOG_CI_END="0.2487653861717288" LOG_CI_START="-0.2495365512402564" LOG_EFFECT_SIZE="-3.8558253426376955E-4" MODIFIED="2009-09-16 19:12:03 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.9975798501351056" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.00000000000001" Z="0.003033212690882618">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="1.7732312900979612" CI_START="0.5629417369060513" EFFECT_SIZE="0.9991125574147813" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="59" LOG_CI_END="0.24876538617172875" LOG_CI_START="-0.2495365512402564" LOG_EFFECT_SIZE="-3.8558253426376955E-4" MODIFIED="2009-09-16 19:06:01 +0200" MODIFIED_BY="[Empty name]" ORDER="134" O_E="-0.010362694300518172" SE="0.2927050246701716" STUDY_ID="STD-Suhonen-2004" TOTAL_1="94" TOTAL_2="99" VAR="11.671848573116057" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.681794374859624" CI_START="1.3159897019371223" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="2.4821750913064964" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.6704123354979714" LOG_CI_START="0.11925249079056507" LOG_EFFECT_SIZE="0.3948324131442683" METHOD="PETO" MODIFIED="2009-09-16 19:08:21 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.0049834002527443765" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="2.808104825207728">
<NAME>Breast tenderness</NAME>
<GROUP_LABEL_1>LNG-IUS 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral contraceptives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.681794374859624" CI_START="1.3159897019371223" DF="0" EFFECT_SIZE="2.4821750913064964" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" I2="0.0" ID="CMP-004.03.01" LOG_CI_END="0.6704123354979714" LOG_CI_START="0.11925249079056507" LOG_EFFECT_SIZE="0.3948324131442683" MODIFIED="2009-09-16 19:08:21 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.0049834002527443765" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="2.808104825207728">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="4.681794374859624" CI_START="1.3159897019371223" EFFECT_SIZE="2.4821750913064964" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="18" LOG_CI_END="0.6704123354979714" LOG_CI_START="0.11925249079056507" LOG_EFFECT_SIZE="0.3948324131442683" MODIFIED="2009-09-16 19:04:01 +0200" MODIFIED_BY="[Empty name]" ORDER="135" O_E="8.673575129533678" SE="0.323754021066363" STUDY_ID="STD-Suhonen-2004" TOTAL_1="94" TOTAL_2="99" VAR="9.540467529329646" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="3.075131681105051" CI_START="0.9968739778904779" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="1.7508622879827598" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.48786371755951263" LOG_CI_START="-0.0013597405510036192" LOG_EFFECT_SIZE="0.24325198850425447" METHOD="PETO" MODIFIED="2009-09-16 19:12:09 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.05128718589202504" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="1.9490689938600132">
<NAME>Acne</NAME>
<GROUP_LABEL_1>LNG-IUS 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral contraceptives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="3.075131681105051" CI_START="0.9968739778904779" DF="0" EFFECT_SIZE="1.7508622879827598" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" I2="0.0" ID="CMP-004.04.01" LOG_CI_END="0.48786371755951263" LOG_CI_START="-0.0013597405510036192" LOG_EFFECT_SIZE="0.24325198850425447" MODIFIED="2009-09-16 19:12:09 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.05128718589202504" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="1.9490689938600132">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="3.075131681105051" CI_START="0.9968739778904778" EFFECT_SIZE="1.7508622879827598" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="0.48786371755951263" LOG_CI_START="-0.0013597405510036673" LOG_EFFECT_SIZE="0.24325198850425447" MODIFIED="2009-09-16 19:09:11 +0200" MODIFIED_BY="[Empty name]" ORDER="136" O_E="6.782383419689118" SE="0.2873722809892915" STUDY_ID="STD-Suhonen-2004" TOTAL_1="94" TOTAL_2="99" VAR="12.109054941072243" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="19.75159614181722" CI_START="3.2384677306464784" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="7.9978063701265345" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.2956021970548315" LOG_CI_START="0.510339573932141" LOG_EFFECT_SIZE="0.9029708854934864" METHOD="PETO" MODIFIED="2009-11-09 17:48:24 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="6.559217003505678E-6" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="4.50751216864924">
<NAME>Absence of menstrual bleeding</NAME>
<GROUP_LABEL_1>LNG-IUS 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral contraceptives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="19.75159614181722" CI_START="3.2384677306464784" DF="0" EFFECT_SIZE="7.9978063701265345" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" I2="0.0" ID="CMP-004.05.01" LOG_CI_END="1.2956021970548315" LOG_CI_START="0.510339573932141" LOG_EFFECT_SIZE="0.9029708854934864" MODIFIED="2009-09-16 19:12:15 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="6.559217003505678E-6" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="4.50751216864924">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="19.75159614181722" CI_START="3.2384677306464784" EFFECT_SIZE="7.9978063701265345" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="1.2956021970548315" LOG_CI_START="0.510339573932141" LOG_EFFECT_SIZE="0.9029708854934864" MODIFIED="2009-09-16 19:10:17 +0200" MODIFIED_BY="[Empty name]" ORDER="137" O_E="9.7720207253886" SE="0.46126715193494344" STUDY_ID="STD-Suhonen-2004" TOTAL_1="94" TOTAL_2="99" VAR="4.6999684555290075" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3015387506771188" CI_START="0.41976924102244817" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.7391521721087204" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="58" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.11445710287530637" LOG_CI_START="-0.376989387915682" LOG_EFFECT_SIZE="-0.13126614252018784" METHOD="PETO" MODIFIED="2009-09-16 19:12:21 +0200" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.2950908209189608" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="1.0470190205854557">
<NAME>Prolonged bleeding</NAME>
<GROUP_LABEL_1>LNG-IUS 20</GROUP_LABEL_1>
<GROUP_LABEL_2>Oral contraceptives</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3015387506771188" CI_START="0.41976924102244817" DF="0" EFFECT_SIZE="0.7391521721087204" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="58" I2="0.0" ID="CMP-004.06.01" LOG_CI_END="0.11445710287530637" LOG_CI_START="-0.376989387915682" LOG_EFFECT_SIZE="-0.13126614252018784" MODIFIED="2009-09-16 19:12:21 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.2950908209189608" STUDIES="1" TAU2="0.0" TOTAL_1="94" TOTAL_2="99" WEIGHT="100.0" Z="1.0470190205854557">
<NAME>At 1 year</NAME>
<DICH_DATA CI_END="1.3015387506771188" CI_START="0.41976924102244817" EFFECT_SIZE="0.7391521721087204" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="58" LOG_CI_END="0.11445710287530637" LOG_CI_START="-0.376989387915682" LOG_EFFECT_SIZE="-0.13126614252018784" MODIFIED="2009-09-16 19:11:29 +0200" MODIFIED_BY="[Empty name]" ORDER="138" O_E="-3.626943005181346" SE="0.28867810138999006" STUDY_ID="STD-Suhonen-2004" TOTAL_1="94" TOTAL_2="99" VAR="11.999753349083198" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-004.07" MODIFIED="2009-09-16 19:49:47 +0200" MODIFIED_BY="[Empty name]" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Hormonal reasons for discontinuation</NAME>
<TR>
<TH>
<P>Hormonal reasons for discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.07.01" MODIFIED="2009-09-16 19:48:54 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA MODIFIED="2009-09-16 19:48:33 +0200" MODIFIED_BY="[Empty name]" ORDER="120" STUDY_ID="STD-Suhonen-2004">
<TR>
<TD>
<P>4/1128 women months vs. 9/1188 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-004.08" MODIFIED="2009-09-16 19:52:03 +0200" MODIFIED_BY="[Empty name]" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation because planning pregnancy</NAME>
<TR>
<TH>
<P>Dsicontinuation becasue planning pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.08.01" MODIFIED="2009-09-16 19:52:03 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA MODIFIED="2009-09-16 19:52:03 +0200" MODIFIED_BY="[Empty name]" ORDER="121" STUDY_ID="STD-Suhonen-2004">
<TR>
<TD>
<P>0/1128 women months vs. 2/1188 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-004.09" MODIFIED="2009-09-16 19:54:03 +0200" MODIFIED_BY="[Empty name]" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation for personal reasons</NAME>
<TR>
<TH>
<P>Discontinuation for personal reasons</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.09.01" MODIFIED="2009-09-16 19:54:03 +0200" MODIFIED_BY="[Empty name]" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA MODIFIED="2009-09-16 19:53:50 +0200" MODIFIED_BY="[Empty name]" ORDER="122" STUDY_ID="STD-Suhonen-2004">
<TR>
<TD>
<P>4/1128 women months vs. 14/1188 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-01-03 17:00:30 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>P4-IUS vs. non-medicated IUD</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Pregnancy</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.01.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="123" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>3/3389 women months vs. 28/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Continuation of method</NAME>
<TR>
<TH>
<P>Continuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.02.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="124" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>Life table probabilities (SE) = 74.4 (2.4) vs. 65.8 (2.8)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Expulsion</NAME>
<TR>
<TH>
<P>Expulsion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.03.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="125" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>25/3389 women months vs. 23/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Ectopic pregnancy</NAME>
<TR>
<TH>
<P>Ectopic pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.04.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="126" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>0/3389 women months vs. 1/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: all</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.05.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="127" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>29/3389 women months vs. 22/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.06" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation because planning pregnancy</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.06.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="128" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>10/3389 women months vs. 6/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-005.07" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Discontinuation for personal reasons</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-005.07.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="129" STUDY_ID="STD-Newton-1979">
<TR>
<TD>
<P>8/3389 women months vs. 15/2953 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-01-03 17:00:43 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>P4-IUS vs. IUDs &lt;=250mm2</NAME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.01" NO="1" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Pregnancy</NAME>
<TR>
<TH>
<P>Pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.01.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="130" STUDY_ID="STD-Fylling-1979">
<TR>
<TD>
<P>7/1729 women months vs. 3/1483 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="131" STUDY_ID="STD-Larsen-1981">
<TR>
<TD>
<P>4/1996 women months vs. 4/1943 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Continuation of method</NAME>
<TR>
<TH>
<P>Continuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.02.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="132" STUDY_ID="STD-Larsen-1981">
<TR>
<TD>
<P>150/1996 women months vs. 142/1943 women months <BR/>Life table probabilities (SE) = 76.2 (3.1) vs. 76 (3.2)</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Expulsion</NAME>
<TR>
<TH>
<P>Expulsion</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.03.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="133" STUDY_ID="STD-Fylling-1979">
<TR>
<TD>
<P>2/1729 women months vs. 15/1483 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Ectopic pregnancy</NAME>
<TR>
<TH>
<P>Ectopic pregnancy</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.04.01" NO="1" STUDIES="2">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="134" STUDY_ID="STD-Fylling-1979">
<TR>
<TD>
<P>2/1729 women moths vs. 0/1483 women months</P>
</TD>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="135" STUDY_ID="STD-Larsen-1981">
<TR>
<TD>
<P>1/1996 women months vs. 0/1934 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="1" ID="CMP-006.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Menstrual reasons for discontinuation: bleeding &amp; pain</NAME>
<TR>
<TH>
<P>Discontinuation</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-006.05.01" NO="1" STUDIES="1">
<NAME>At 1 year</NAME>
<OTHER_DATA ORDER="136" STUDY_ID="STD-Fylling-1979">
<TR>
<TD>
<P>35/1729 women months vs. 10/1483 women months</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-11-09 17:49:09 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-11-08 18:48:46 +0100" MODIFIED_BY="[Empty name]" NO="1" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 LNG-20 IUS vs. IUDs &gt;250mm2, outcome: 1.3 Planned pregnancy after discontinuation of method.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq0AAADgCAMAAAAe268CAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAVtklEQVR42u1dTY8cxRmuHc9SNto1cWYDu0BkFAkrH+QULrnkD6SU
EOUPcOXGj+DEhV/AlXMk6gQ/AOWQQyQsEksIOawSm/UqTuzAFrvrzUx3dddnV1fPVPV0zzwPrLun
67v66bfeqn77rR1KAGAkmKALALAVAMBWYIsxHVBdWPEv9wbxUDrepQTekpwR3k/znHLrQFkFoyae
1HlqOuRqDkm2cl7+NfVgsHvjbgTnTnTWZwO14llE3cKpOd+2ag5JthpPr3yGiwNbPKNscZRPahWl
vBgrXIuknHiSG0X200Am5Q7RBBRnShTVB7tORo/krPMAqzlIvbV4Oot/WPGkViSbnxb9VD/gTAV2
ug1uclVkD2St2+QpsnyAtIMVweiRnHUeYjWnZNAw2sidB5SvmvswG820A6sH0lI+8T5Vl6FVc7hs
ZfozvLyuOjwdp0vtOVOTFEmAhh7ZimoOl608NEHno2Qr7177Uh2qSVFqgVtbzSGvtzK2bGBArWBs
kE0r66amLPLA2FofzKFVc6hs5WUP8LLDLC2IG90TryLpmbrJeU+drmqhF1mdlnMT7aDXiZczTVXr
jHUeYjV3YNUCjAZ48wqArQAAtgJgKwCArQAAtgLbCf1dllwas0yaQgtlVYr2mG0I2Lb6TaysBMxf
i67ZxuVaBjBpJMbtGNWZUUCL2ajsSm8X6jnXhmnFi02usqntypLdguHVUGdraYvHeCd70SJFkueG
h3vRja63myXKNjbXmILc90BaXzF/Bry1vxmr4+l3SgWtdguGXcOp53bVNom1NWktQzyGoDKsCudE
GY7WUZlmTspb6a/SKvvVRgNJnxXm6tm25lo91MzTRlIVxjpnrRnxMmLKbu9ox3TBnuqd1nBraOit
8mWZMbYzqxbcsAe3XiRX1qdyUHEtI1nUa1LXALXRQFK3wuQtRpTx2cblqqyNbLujgN1t2GzUqazf
lInltHYYcA0nppx3y5C19spEJ0Wr9U7g4Zq3j9klcatvWsYxxtJny7vZwfC2ZgY7oC6Qh/uMS+uS
zLwdXA2nrhbQ6d50TRGp9zk6H4tQz71P+crZRhhqskiZFTYbVQZ3ho2TUV19WlvMh1lKK9LB13Dq
G9u68jU9uK8c1q7hp8/Wnysv7ZOkjOGd2tT+0BHWkCvPa4c++BpOLK3VERihdQctBTOEDGuSPyyC
/NxTmxUNzjJl6+kJ1im2v99rXZGxKkt5xkzVhJlmjwmH3IHWcGJqaJpFo2a+aCpx3JeCqyGCm3V0
IzTrrd5iLAtLj1qpWWGmybY1V3+nmN3lH3b8ZqOheGZ/c6sd6Y1zB1zDOPvWTsUw3pSAjfQLldVb
3posRZy8DRtCDadRXO10B3hf3+UPDsu1HGRNLFsBAABGjj/2W9wUshVYAf3SBxaDwHgAtgLjwdSa
/fNqFcCx1qyWBpgTAABrkK3qhYwyvWl0d8rQecAaZWvNP+65Vlh3MGW1yXQJW9uOkn49oQJbLFs1
q3nNZRyxongDDH+rJJ/fZgBsdfhXawKtlqqm7SgfiFc0AGsCQVTmOBCqQD9rAiEykhbLaw6yAr3L
1rmMZLrxoqYdcD9L/bajANCLJhAyReSNnzZr/lYBIAcS2GBh9N9e9GzJOF2dqyArMBa2gqrAeNgK
bDUuemUUbLCAka8JAADYCgBgKwC2AsCQ1wQEKT4LE/KNgTDfHJQ/RfnlmKg+IBO5vyOzC2yOGBet
U7Zl8KJfSExnqAs0qmfqKCojIjOmRtWEEUqsiquWC0K3ha1lo2ndYGrfOBln/ieo1oN5yWoVGCIW
iYjWKVsZ7DbU3xnaBUFjyGqVo3W5WTXh3BAntLxABdkWtqqeKJtednotQ9fTEXSd2VJXCibsDJWL
fzBrEsQZu8UEy5WIp2Irdbqo7CXa0uHrRt6aWDyinVPEPTENeolsWzg0A/gy1Mz5clNnK60VI1oP
ZLRx/OqNprV0j9Zz4xlI2/TcpRTBxYAkOiatFIEAy81QK3sqCNl4TyZT+2FvkQnljagOoo/+KaS7
LLBNlLVFa1BMWwpfSs8Q3ZPScNv8NRM0riUbOcuK7FGl4PfURW2lyJrQTkTNEXe54VnQ9rYtFbpR
mDSJUBocZ6tJKqW5h59IvUPWRKQlYH/aDg0U52ubsEO3An69NagJENqnltStwOh6iXLO0hI/Llge
hJad1F1imeqrjcrVd6EpdLMB/62DRMsacEqdZSWwP4VnQv1oAsC66dprslGuCQBDAV1yurmOkfKn
5Ip8c3X6M7Iz/+9vWYu6BroCS+LsDx8/nlx/+uz+ycm335FHV/84Obl6fn//hadn70FvBQaD3Zcu
z5+dP2oMP5juPpld+/v1nGzVNz3UfLn6dqzXAmN2pO/jQ16mXBwmzFM5UOCB8lSxdQre/vWy5S23
7n5mu2lkRrCWxK5I/g+Qb7//9t75D7+Ii3w42Z188kaeWRYjvu2imfdUXVG+XgtfLty8GzxyD8I0
xArv+bzUA1DuI+3xUqOXZ+yiHc0Z11tuXQ73utBV1XBCq5pmHPZvHx3Obol7bz0+fvjFTF5sOT4Q
9796ff+F2Y1X/5NnliX3J2PyIde3qfftWO8IW+LdkZ6P04ELJ57mkcjHj/E4shLeUIRfEHvlfFZ8
/suj8998enA6O53TsPw77XB8NPuGPH5lbzJ5bvJwep5Mtrr7eZrb1Jenuvy1NgNlMfcml2jNcwND
HpbSPQvhHqyffj2YeRS15Phu5/DFd2++fvbV8Ucnc+rNryz9d3ry8Ov7Z0/3bx0cvXqWgq3c5mvj
vqr+zs+yI/26pWv5aLqcjRCcLd3AHcHZosUYwVbchNu8avjyFXL1Zdosr3auyH4S2cp5hBC0O0XS
V6pUc8nL+Br8t1SbHg/EaVzHbih1Jh5uGg+FJlbYJd44fnDy8X/3Pn/tB0cvFrroCn8Hhy+/9pO9
J49PHhwvrw5Mbep1JGvuHem7TLJKgrAcmfO8decRTVsqNAXOfzXXCcjV3d+dX15IXbQY3GOPi5UB
8STJatbU22ksXiWScym1T5HaUp0x3pcDQn1yyNfFUj16LIGKiWyzo+ZCZmrzXjX9NUPzQ7Jt7zN2
cfhmUeCpDGk8zq5Nv53dpde15CvCt95a9mDVj4xoa6q8Xlfl1T1h9SJhtZ0WsxcfeR+eE6tlR540
z7rdjeXpq53c2w2hGrNqvURbbWFmlp4LTaF9CYfdi5cuLy5PGsNnu9N3Ppz+8zx1uau9y4rtHLh4
TdarjA+mo89uHP3iL8UbrZmUp7Nf//na7uoLVY1YzU7g3p17UfHugKwdcIc0d2sbWcm9/ur5Hnny
879+f+O5H9+c7F1/fu/3Xx998tsPzv73lDzLVSLsBIDV12L6AuxbgfEAbAXAVgAAWwGwFQDAVgBI
CW251XK7KEz3oAHk/So42n/rILIFemLrMB0pRftvHUS2QO+agBBCOjMpzqzLRAXM43hjpgQdVbZA
X7LVFDvUljzC8vFeSycKGQWsja1BAUQNF+W0D3HV0X9rJ2WAQm/dGLY2ubVzmZPzrkf5b11NfQU2
gK3C8MMYdHuf/a7THEQFxj/LapSuxXqPtc8IyTJKOzkLkBXwydZqVC/2s1HDrz7YWwN/ufNNntuf
yWFsnP9WYMhspda/tPpfG4upL0rGW06zaAI089QQWIcmAABgKwCArQDYCgBgKwCArcDms1Vo/5pn
kRANG6PH5Cjc0L43lAW2SrZ6N4VeJTkAtLPVtnDVTViFKI1cNQtXPZqKXxBQODnaaasspO2slh2p
Q/KZzwJjgteqxbVwVafFPo+WhasyZaLVbry0KUcnrbHZtJmd0PeJxot9YBo3bpuGrCI0elsWsB6S
WW89nZ3M8VoUiGBrvZFzxLxIROqnPrq2jupiJf0X2CpNgND2mQ9dfoIk2rZmdyNAygKhNQHRLuga
xKslTb0m/0JLIXy5CycE4hWY+kdvzcK1Vi9rQ9PizDAM1X5JqgorsM6R1FkUR3Wo4lInAj6fAkos
5b+1ZXoeOXt3eQ2MDT37b+3sGlu0apGgHzAUttIEMYx44Daw8iwLAMBWAABbAbAVAIY5yxLeWU+1
ztRpNqQbqlTJrRyUIYu3VO2KsPysSsMZpz7amm/pO6aIhRWKzWRryM5pxXvusNdaGhBeky2NzdoF
QdvSyDMqnxLQdaM1AaEZmUpjVsvUlTR4c3UNUatMLAvZ0hQ2/lnozDi8edhw2WoJKd0k1TJ1JQFv
riZFDEtZ3R6WSuFHbE2EOrURASnvT1PpLXXdgY1la4tIM1wN2t5cI4lBfQRseUNmON4ihoejLooH
sGFslQIr3pJEeE/d36K7TiyUZbaIsGNcUm8AxstW2j7ramKHY5nawXt2gyYQrIUI5Qv5uiWaQOxY
SgW1mSGCpFFar0d6+h+E0EdZ4OO2s9XymCpM+1bi/jKNYI1ZkZFIs5Atp09UrTFQXxUEdfNpnDSp
NGZNIWE3Bzuju5dd2Qe2ZkTP9q3je/PacbMMkHWDMEI7AZoxNgC2AgDYCoCtAAC2AgDYCoCtAAC2
AgDYCoCtAAC2AgDYCoCtAAC2AgDYCoCtAAC2AuPG7s7hj969uX9rdvTy7bO8Re3AWhlYEmd32Y1/
X57MTsufi+PBznQ6/dd318FWYDji9KXL82fnjxrDD6a7T2bX/n49I1tZ8W/9WZj6QIzJi/MrrIxR
ROVscV5HK4PmcXv+ssyoJdNbkCLPsk3Ek61eniq2TsHbv7BjRhrZqeVvbrSEGcFaErsiLGnrfbj9
/tt75z/8Ii7y4WR38skbefRWzss/nbvWrWOLCGW3FbHNrq/uK1sPWc1KJHoAiuePcx4sTxVbnfHY
GhOnU0n11NctYfUN4m5nG+VmpOrZ7aPD2S1x763Hxw+/mMmLLccH4v5Xr++/MLvx6n/SVGLaIFCY
Lkqr3rKFgiaBi0vlOV8LW3OAE0+LSeQT2SZamVVKC9eM4F5Hr89/eXT+m08PThd6qfw77XB8NPuG
PH5lbzJ5bvJwep56TaB8THk5lmmiyrg/jLGYG9GjaM1zA1kjh3jCZyHcqbVA0IOZpp5lw3c7hy++
e/P1s6+OPzqZU29+Zem/05OHX98/e7p/6+Do1bOEbDX6s4mUJYtZK29HL13Lp9XlbITgbOkZ7gjO
Fi3GCLbi8sBztTy+fIVcfZk2y6udK7Kfh63OXZL0lfrTXPLOn2w+BFZJCdP8ePVN8k49U6pRPNw0
HgpNrLBLvHH84OTj/+59/toPjl4sdNEV/g4OX37tJ3tPHp88OF5eHZh2Iauaug4OrLxzeerH8j6S
rRpraLxnJLd/n/NfzXUCcnX3d+eXF1IXLQb32ONiZUA8SbKaNe3er9rkU3UTZ4znvqvhYZVVFePr
YqkePZZAixW/Mpm3sEJmqqZVsdQPTnrqdcm2vc/YxeGbRYHypUDzcXZt+u3sLr2uJU/OVs6KFZgF
/bg+rhbLq6V2JKMYUyr92tqUA55WezPaGYig4vl6Jm5g4GZhTtHGhXBoVkH75vyfT/cuXrq8uDxp
jDXbnb7z4fSf8yH/+IWUpXd4lxVLBDYMVXa8CHYg44Pp+7MbR7/4S/FGq375+us/X9tdfaGqEdfi
VYF7d+5FxbsDsq6GO6S5p9vISu71V8/3yJOf//X7G8/9+OZk7/rze7//+uiT335w9r+n5FmuEmEn
AKy+FtMXYDEIjAdgKwC2AgDYCoCtAAC2AkBKaMutcq+UaklL26+tZZUr77Yp1bZdiTe8yJQt0BNb
6SC362nYnHug2QK9awJCCLlHYHFmXSYqYB7HGzMl6KiyBfqSrabYobbk0X8IqkknChkFrI2tQQFE
BW3aeT0XWYXMObXwFrTTtvbAwNlqEkQ0BZC8d53KnYZpBl0DY8LmsLW4l17ZST1iOO9dpzmICox/
ltUoXYv1nlp3JQFZm1IPyFMAyLoZsrUa1RfzJ2341Qd7a+AvYmbSBGTOqQsQ5Uor9NYRs5Va/9Lq
f20spr4oGW85zaIJ0MxTQ2AdmgAAgK0AALYCYCsADAH4inBzEVyki13BC8dbJXSJXCBbgXFqAkL7
1zyLfZg9bxNicxRuaK4XAwD0VuJbvBSrJQcAHdMmQUcXr3uotK0vDK9qa3sq7QfKAM0Ef/FL1PEL
AmrvaWWOxEpbZVGZJegW/VUITPyXU1yXDoyOt0po93jTJr3WtFtVpyVtrYDalGlhUOiTkypHJ211
qOK5pcJUKtlYN8pZVgNbRVy7ddM9txzLAtZTE+utJ3VC8VoUaJet1TAdMy8SkaLcR9dWwS9W0n+B
7dJbaftgQpefIJlms1ERIGWB0JqAaBd0DeLVkqZek3+hpRC+3IUTAvGaUm2Nfv5pttAlcpn6R2/N
wrVWL2tD0+LMmKVrvwS1FWc9upyKlRSWiwH1mkB9bkXA51MrLAp43EOQuJUWI15DxPDrssib5ste
XzxSWOrNa8tcL3Iq6PIaSExWtZQiiPvtcnilRU9MG3lGo0rvTCdRyzYjsPPbATFHErICPfN26YG6
maxJdA0fWWmXWdZKdeiorYDb61ZhuygUOea+wreKmYatwMbLXB8rlxswU2cPGywgr2BOmT3YCtE6
nuzBVpA1Qq8cSPbaCpbwCmZnBSSynmZVhbGqajTFbwWjXRGWn1VpOEOblXVp41XE2uoVCqGUQnu9
VVonBW6rSty8cCpoCwtpdC19GYfXWxsXEzrec5utDnuJE+4EKltDai/+Wd1vp/FEBjYCjf5bdTeu
uotWUb0a9Xlzdf24VpnogVW+In7I6Mw4vHnYRDT6bzVMUi1TVxLw5mpSxLCU1e1hF5eoT39xX8GJ
wNjjT1PpLXXdgY1la4tIM1wN2t5cI4lBfQRseUNmON4ihoejVrUZ2Fy2SoEVb0kimid4EWZUcR8S
GwSkifUGYLxsVa9EIyUUNUf+RuLQCM5T96qgHdN0W0EBxq4JxI6lVFCbGSJIGneJQQS/a6FhWx7w
cdvZanlMFaZ9K3F/mUawxqzISKRZyJL6u1jhW5ejwhLtKp/GSZNKY9YUEnZzMD7PQl3ZB7ZuDsb3
5rXjZhkgK2QrAEC2AgDYCoCtAAC2AkAbW0UJe05dBQYn3t2m6dJ4S5ClNt6GU9ithfZ2gC79LW53
0FVMTzolw5rHhmsC8fatysVbbbkqrNhSwNVSVEa0bF7NUyNHYZZGtBVXrYZWalWgsLPSqwIJO1rZ
qouuTvatRPO7KtQvN5yoDywI9bpqNVzCmv5dPQaxcAoL2doyjHrt9qhxQoMZtTlSoP6IegzRnAGc
wm6XbI2yb03mR02E52r+usApLNhKHPEUGChTDaM0SpLTKFdxcAq7nZqAiN//wPS0KvwxRaSM831q
4KsLnMJCthqDfJR9q+lpVbNu9YaToAGsUwC16wKnsFuO5DZY3gG7v6k3nMJuMv4PyECed2++ZiEA
AAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-11-09 17:49:09 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 LNG-20 IUS vs. IUDs &gt;250mm2, outcome: 1.4 Absence of menstrual bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqsAAAFQCAMAAACveMeEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-11-08 18:49:54 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 LNG-20 IUS vs. IUDs &gt;250mm2, outcome: 1.5 Prolonged bleeding.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqsAAAFQCAMAAACveMeEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-11-08 18:50:13 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-002.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 LNG-20 IUS vs. IUD&lt;=250mm2, outcome: 2.3 Planned pregnancy after discontinuation of method.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAnkAAACwCAMAAABEr4jGAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-11-08 18:50:37 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-002.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 LNG-20 IUS vs. IUD&lt;=250mm2, outcome: 2.4 Headaches.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAq0AAADgCAMAAAAe268CAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2009-11-08 20:26:15 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2009-11-08 20:26:15 +0100" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS MODIFIED="2009-11-08 20:26:15 +0100" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>